C:\STNEXP4\QUERIES\098339[redacted].str





chain nodes :
14
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
2-14
ring bonds :
1-2 1-5 2-3 3-4 4-5 4-6 5-9 6-7 7-8 8-9
exact/norm bonds :
2-14
exact bonds :
1-2 1-5 2-3 3-4 4-5 4-6 5-9 6-7 7-8 8-9
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom
14:Atom

C:\STNEXP4\QUERIES\098339[redacted]a.str



not



```
chain nodes :
    25
ring nodes :
    1  2  3  4  5  6  7  8  9  14  16  17  18  19  20  21  22  23  24
chain bonds :
    2-14  24-25
ring bonds :
    1-2  1-5  2-3  3-4  4-5  4-6  5-9  6-7  7-8  8-9  14-16  14-20  16-17
    17-18  17-21  18-19  18-24  19-20  21-22  22-23  23-24
exact/norm bonds :
    2-14  17-21  18-24  21-22  22-23  23-24  24-25
exact bonds :
    1-2  1-5  2-3  3-4  4-5  4-6  5-9  6-7  7-8  8-9
normalized bonds :
    14-16  14-20  16-17  17-18  18-19  19-20
isolated ring systems :
    containing 1 :


Match level :
    1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom
    14:Atom  16:Atom  17:Atom  18:Atom  19:Atom  20:Atom  21:Atom  22:Atom
    23:Atom  24:Atom  25:CLASS
```

```
=> d his

     (FILE 'HOME' ENTERED AT 16:06:42 ON 11 DEC 2002)

     FILE 'REGISTRY' ENTERED AT 16:06:46 ON 11 DEC 2002
L5             STRUCTURE UPLOADED
L6             QUE L5
L7           5 S L6
L8         475 S L6 SSS FUL

     FILE 'CAPLUS' ENTERED AT 16:11:45 ON 11 DEC 2002
L9         602 S L8
L10        ANALYZE L9 1- RN HIT :     471 TERMS

     FILE 'REGISTRY' ENTERED AT 16:12:27 ON 11 DEC 2002
L11          1 S 151096-09-2/RN
L12          1 S 144194-96-7/RN
L13          1 S 186826-86-8/RN

     FILE 'REGISTRY' ENTERED AT 16:16:14 ON 11 DEC 2002
L14            STRUCTURE UPLOADED
L15            QUE L14
L16        231 S L15  SUB=L8 FUL
L17        244 S L8 NOT L16

     FILE 'CAPLUS' ENTERED AT 16:22:34 ON 11 DEC 2002
L18         28 S L17

=> d l6
L6 HAS NO ANSWERS
L5              STR
```




```
Structure attributes must be viewed using STN Express query preparation.
L6              QUE  ABB=ON  PLU=ON  L5


=> d l15
L15 HAS NO ANSWERS
L14             STR
```



Structure attributes must be viewed using STN Express query preparation.
L15 QUE ABB=ON PLU=ON L14

=> d bib abs hitstr l18 1-28

L11 1 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo- (9CI)
MF C21 H24 F N3 O4
CI COM

Absolute stereochemistry. Rotation (-).



151096-09-2
466 ref.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> d scan l12

L12 1 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 3-Quinolinecarboxylic acid, 8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, monohydrochloride (9CI)
MF C20 H21 Cl F N3 O3 . Cl H

Absolute stereochemistry.

144194-96-7
66 ref



● HCl

ALL ANSWERS HAVE BEEN SCANNED

13 1 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, monohydrochloride (9CI)
MF C21 H24 F N3 O4 . Cl H

Absolute stereochemistry. Rotation (-).



● HCl

L13
186826-86-8
34 ref

ALL ANSWERS HAVE BEEN SCANNED

=

L8 ANSWER 1 OF 28 CAPLUS COPYRIGHT 2002 ACS
AN 2002:835034 CAPLUS
TI Synthesis and Structure-Activity Relationships of Novel 7-Substituted 1,4-Dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic Acids as Antitumor Agents. Part 1
AU Tomita, Kyoji; Tsuzuki, Yasunori; Shibamori, Koh-ichiro; Tashima, Masanori; Kajikawa, Fumie; Sato, Yuji; Kashimoto, Shigeki; Chiba, Katsumi; Hino, Katsuhiko
CS Chemistry Research Laboratories, Dainippon Pharmaceutical Co. Ltd., Osaka, 564-0053, Japan
SO Journal of Medicinal Chemistry (2002), 45(25), 5564-5575
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
GI



HCl

I

AB Title compds., e.g. I (R = H2NCH2CH2NH, 1-pyrrolidinyl, 3-hydroxy-1-pyrrolidinyl), possess moderate cytotoxic activity. Structure-activity relationships of title compds. were investigated by changing substituents at N-1 and C-7 positions and the core ring structure itself and evaluated the synthesized compds. against several murine and human tumor cell lines. The 2-thiazolyl group at the N-1 position of the naphthyridine structure is the best substituent for antitumor activity and regarding core ring structure, the naphthyridine deriv. is the most active followed by pyridopyrimidine analog. At the C-7 position, aminopyrrolidine derivs. are more effective than other amines or thioether derivs. I (R = 3-amino-4-methoxy-1-pyrrolidinyl, 3-amino-3-methyl-1-pyrrolidinyl, 3-aminopyrrolidinyl) were detd. to be effective in vitro and in vivo antitumor assays, and their activity was comparable to that of etoposide.
IT **475468-86-1P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and structure-antitumor relationships of naphthyridinecarboxylates)
RN 475468-86-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



● HCl

RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 2 OF 28 CAPLUS COPYRIGHT 2002 ACS
AN 2002:792123 CAPLUS
DN 137:294972
TI Preparation of substituted bicyclo[]-4-amino-pyridopyrimidine derivatives as kinase inhibitors
IN Bhattacharya, Samit Kumar; Kath, John Charles; Morris, Joel
PA Pfizer Products Inc., USA
SO Eur. Pat. Appl., 24 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1249451	A2	20021016	EP 2002-252428	20020403
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2002322178	A2	20021108	JP 2002-102413	20020404
PRAI	US 2001-283910P	P	20010413		

OS MARPAT 137:294972
GI



I



II

AB Title compds. I [R1-2 = H, alkyl; R3 = (CR1R2)mR4; m = 0-6 or NR1R3 = (CR1R2)n-indol(in)yl; n = 0-2; X = N and Y is CR9 or X = CR9 and Y = N; R9 = fused-ring bicyclic, bridged bicyclic or spirobicylic group] were prepd. For instance, 4-chloro-6-fluoropyrido[3,4-d]pyrimidine (prepn. given) was reacted with [3-methyl-4-(pyridin-3-yloxy)phenyl]amine (t-BuOH/ClCH2CH2Cl, reflux, 1 h) and the product coupled to (3-azabicyclo[3.1.0]hex-6-yl)carbamic acid tert-Bu ester (EtOH, sealed tube, 105.degree., 24 h) and finally deprotected to give II. Selected compds. of the invention had IC50 in the range of 1 nM to 1 pM for erbB-2 receptor kinase. I are used for the treatment of hyperproliferative disorders.

IT **468734-02-3P**, [4-(2-Fluorophenoxy)-3-methylphenyl]-[6-

(hexahydropyrrolo[3,4-c]pyrrol-2-yl)pyrido[3,4-d]pyrimidin-4-yl]amine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of fused arylamino-substituted pyridopyrimidines as erbB-2 kinase inhibitors)

RN 468734-02-3 CAPLUS

CN Pyrido[3,4-d]pyrimidin-4-amine, N-[4-(2-fluorophenoxy)-3-methylphenyl]-6-(hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)- (9CI) (CA INDEX NAME)



applicants

L18 ANSWER 3 OF 28 CAPLUS COPYRIGHT 2002 ACS
AN 2001:798225 CAPLUS
DN 135:344471
TI Preparation of diazabicyclic compounds as central nervous system active agents
IN Schrimpf, Michael R.; Tietje, Karin R.; Toupence, Richard B.; Ji, Jianguo; Basha, Anwer; Bunnelle, William H.; Daanen, Jerome F.; Pace, Jennifer M.; Sippy, Kevin B.
PA Abbott Laboratories, USA
SO PCT Int. Appl., 190 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001081347	A2	20011101	WO 2001-US13798	20010427
WO 2001081347	A3	20020131		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2002019388	A1	20020214	US 2001-833914	20010412
BR 2001007246	A	20021001	BR 2001-7246	20010427
PRAI US 2000-200111P	P	20000427		
US 2000-559943	A2	20000427		
US 2001-833914	A	20010412		
WO 2001-US13798	W	20010427		

OS MARPAT 135:344471
GI



I

AB Diazabicyclic compds. (I; e.g. cis-2-(3-pyridinyl)octahydropyrrolo[3,4-c]pyrrole dihydrochloride), pharmaceutical compns. of these compds., and use of said compns. to control synaptic transmission in mammals are claimed. In I: A = covalent bond, CH2, CH2CH2, and CH2CH2CH2; B = CH2 and CH2CH2, provided that when A is CH2CH2CH2, then B is CH2; Y = covalent bond, CH2, and CH2CH2; Z = covalent bond, CH2, and CH2CH2, provided that when Y is CH2CH2, then Z is a covalent bond and further provided that when Z is CH2CH2, then Y is a covalent bond. R1 = optionally substituted phthalazin-1-yl, pyridin-3-yl, pyrazinyl, pyrimidin-5-yl, pyridazin-3-yl, quinolin-3-yl, thieno[3,2-b]pyridin-2-yl, furano[3,2-b]pyridin-2-yl, thieno[3,2-b]pyridin-3-yl, furano[3,2-b]pyridin-3-yl, furano[3,2-b]pyridin-

6-yl, thieno[3,2-b]pyridin-6-yl, furano[2,3-b]pyridin-5-yl, thieno[2,3-b]pyridin-5-yl, isothiazol-5-yl, isoxazol-5-yl. R9 = H, alkoxycarbonyl, alkyl, amino, aminoalkyl, aminocarbonylalkyl, benzyloxycarbonyl, cyanoalkyl, dihydro-3-pyridinylcarbonyl, hydroxy, hydroxyalkyl, and phenoxycarbonyl. Values are reported for nicotinic acetylcholine receptor binding potencies and effectiveness of nicotinic acetylcholine receptor ligands as analgesic agents and in the formalin test for some of the claimed compds. Ninety-six example prepns. are given but the methods of prepn. are not claimed. The crystal and mol. structures of (3aS,6aS)-5-[(4-nitrophenyl)sulfonyl]-1-((1R)-1-phenylethyl)octahydropyrrolo[3,4-b]pyrrole and tert-Bu (3S,4S)-4-(hydroxymethyl)-3-[((1S)-1-phenylethyl)amino]-1-piperidinecarboxylate were detd. by x-ray crystallog.

IT **370879-94-0P**, cis-7-(6-Chloro-3-pyridinyl)-2,7-diazabicyclo[3.3.0]octane
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(intermediate; prepn. of diazabicyclic compds. as central nervous system active agents)

RN 370879-94-0 CAPLUS

CN Pyrrolo[3,4-b]pyrrole, octahydro-5-(6-chloro-3-pyridinyl)-, (3aR,6aR)-rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.



514-338
546-276.7

IT **370879-59-7P**, tert-Butyl cis-5-(3-pyridinyl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate **370879-64-4P**, tert-Butyl cis-5-(6-chloro-3-pyridinyl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate **370879-66-6P**, cis-2-(6-Chloro-3-pyridinyl)-5-methyloctahydropyrrolo[3,4-c]pyrrole **370879-68-8P**, tert-Butyl cis-5-(3-quinolinyl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate **370879-70-2P**, tert-Butyl cis-5-[5-(benzyloxy)-3-pyridinyl]hexahydropyrrolo[3,4-c]pyrrole-2(1H)carboxylate **370879-71-3P**, tert-Butyl cis-5-(5-hydroxy-3-pyridinyl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate **370879-73-5P**, tert-Butyl cis-5-(5-methoxy-3-pyridinyl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate **370879-75-7P**, tert-Butyl cis-5-(5-ethoxy-3-pyridinyl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate **370879-79-1P**, tert-Butyl cis-5-(5-propoxy-3-pyridinyl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate **370879-81-5P**, tert-Butyl cis-5-(6-chloro-5-methoxy-3-pyridinyl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)carboxylate **370879-83-7P**, tert-Butyl cis-5-(6-chloro-5-methyl 3-pyridinyl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)carboxylate

370879-88-2P, tert-Butyl cis-5-[5-(2,2,2-trifluoroethoxy)-3-pyridinyl]hexahydropyrrolo[3,4-c]pyrrole-2(1H)carboxylate **370879-90-6P**, cis-1-Benzyl-5-(6-chloro-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole **370880-10-7P**, tert-Butyl (3aR,6aR)-5-(6-chloro-3-pyridinyl)hexahydropyrrolo[3,4-b]pyrrole-1(2H)-carboxylate **370880-17-4P**, tert-Butyl (3aS,6aS)-5-(6-chloro-3-pyridinyl)hexahydropyrrolo[3,4-b]pyrrole-1(2H)-carboxylate **370880-33-4P**, tert-Butyl cis-6-(6-chloro-3-pyridinyl)octahydro-1H-pyrrolo[3,4-b]pyridine-1-carboxylate **370880-35-6P**, tert-Butyl cis-6-(3-pyridinyl)octahydro-1H-pyrrolo[3,4-b]pyridine-1-carboxylate **370880-37-8P**, tert-Butyl (3aR,6aR)-5-(5,6-dichloro-3-pyridinyl)hexahydropyrrolo[3,4-b]pyrrole-1(2H)carboxylate **370880-39-0P**, tert-Butyl (3aS,6aS)-5-(5,6-dichloro-3-pyridinyl)hexahydropyrrolo[3,4-b]pyrrole-1(2H)-carboxylate **370880-41-4P**, tert-Butyl (3aS,6aS)-5-(6-chloro-5-methyl-3-pyridinyl)hexahydropyrrolo[3,4-b]pyrrole-1(2H)-carboxylate **370880-43-6P**, tert-Butyl (3aR,6aR)-5-(6-chloro-5-methyl-3-pyridinyl)hexahydropyrrolo[3,4-b]pyrrole-1(2H)-carboxylate **370880-45-8P**, tert-Butyl (3aR,6aR)-5-(3-pyridinyl)hexahydropyrrolo[3,4-b]pyrrole-1(2H)-carboxylate **370880-47-0P**, tert-Butyl (3aR,6aR)-5-(5-methoxy-3-pyridinyl)hexahydropyrrolo[3,4-b]pyrrole-1(2H)carboxylate **370880-50-5P**, tert-Butyl (3aS,6aS)-5-(3-pyridinyl)hexahydropyrrolo[3,4-b]pyrrole-1(2H)-carboxylate **370880-53-8P**, tert-Butyl (3aS,6aS)-5-(5-bromo-3-pyridinyl)hexahydropyrrolo[3,4-b]pyrrole-1(2H)-carboxylate **370880-56-1P**, tert-Butyl (3aS,6aS)-5-(5-methoxy-3-pyridinyl)hexahydropyrrolo[3,4-b]pyrrole-1(2H)carboxylate **370880-65-2P**, tert-Butyl (3aR,6aR)-5-[5-[(trimethylsilyl)ethynyl]-3-pyridinyl]hexahydropyrrolo[3,4-b]pyrrole-1(2H)-carboxylate **370880-66-3P**, tert-Butyl (3aR,6aR)-5-(5-ethynyl-3-pyridinyl)hexahydropyrrolo[3,4-b]pyrrole-1(2H)-carboxylate **370880-68-5P**, tert-Butyl (3aR,6aR)-5-(5-bromo-3-pyridinyl)hexahydropyrrolo[3,4-b]pyrrole-1(2H)-carboxylate **370880-70-9P**, tert-Butyl (3aR,6aR)-5-(5-cyano-3-pyridinyl)hexahydropyrrolo[3,4-b]pyrrole-(2H)-carboxylate **370880-80-1P**, tert-Butyl cis-3-(3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane-6-carboxylate **370880-90-3P**, cis-3-(6-Chloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane **370880-92-5P**, tert-Butyl cis-3-(6-chloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane-6-carboxylate **370881-03-1P**, tert-Butyl (3aR,6aR)-5-(6-bromo-5-methoxy-3-pyridinyl)hexahydropyrrolo[3,4-b]pyrrole-1(2H)-carboxylate hydrochloride (4:7) **370881-31-5P**, tert-Butyl (3aR,6aR)-5-(6-bromo-5-cyano-3-pyridinyl)hexahydropyrrolo[3,4-b]pyrrole-1(2H)-carboxylate **370881-77-9P**, tert-Butyl (3aR,6aR)-5-(5-vinyl-3-pyridinyl)hexahydropyrrolo[3,4-b]pyrrole-1(2H)-carboxylate **370881-78-0P**, (3AR,6aR)-5-(5-vinyl-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole **370881-82-6P**, tert-Butyl (3aR,6aR)-5-(5-methyl-3-pyridinyl)hexahydropyrrolo[3,4-b]pyrrole-1(2H)-carboxylate **370881-83-7P**, (3AR,6aR)-5-(5-methyl-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole **370881-87-1P**, (3AR,6aR)-5-(6-bromo-5-methyl-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole **370882-03-4P**, tert-Butyl (3aR,6aR)-5-(5-ethyl-3-pyridinyl)hexahydropyrrolo[3,4-b]pyrrole-1(2H)-carboxylate **370882-04-5P**, [5-[(3AR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl]-2-bromo-3-pyridinyl]methanol **370882-06-7P**, tert-Butyl (3aR,6aR)-5-[5-(hydroxymethyl)-3-pyridinyl]hexahydropyrrolo[3,4-b]pyrrole-1(2H)-carboxylate **370882-07-8P**, tert-Butyl (3aR,6aR)-5-[6-bromo-

5-(hydroxymethyl)-3-pyridinyl]hexahydropyrrolo[3,4-b]pyrrole-1(2H)-carboxylate **370882-09-0P**, tert-Butyl (3aR,6aR)-5-(6-bromo-5-vinyl-3-pyridinyl)hexahydropyrrolo[3,4-b]pyrrole-1(2H)-carboxylate **370882-10-3P**, (3AR,6aR)-5-(6-bromo-5-vinyl-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole **370882-11-4P**, [5-[(3AR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl]-2-bromo-3-pyridinyl]acetonitrile **370882-13-6P**, tert-Butyl (3aR,6aR)-5-[6-bromo-5-[[(methylsulfonyl)oxy]methyl]-3-pyridinyl]hexahydropyrrolo[3,4-b]pyrrole-1(2H)-carboxylate **370882-15-8P**, (3AR,6aR)-5-[6-bromo-5-(methoxymethyl)-3-pyridinyl]octahydropyrrolo[3,4-b]pyrrole **370882-17-0P**, tert-Butyl (3aR,6aR)-5-[6-bromo-5-(methoxymethyl)-3-pyridinyl]hexahydropyrrolo[3,4-b]pyrrole-1(2H)-carboxylate **370882-62-5P**, tert-Butyl (1S,5R)-3-(5-cyano-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane-6-carboxylate **370882-67-0P**, tert-Butyl (1S,5R)-3-(6-chloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane-6-carboxylate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of diazabicyclic compds. as central nervous system active agents)

RN 370879-59-7 CAPLUS
CN Pyrrolo[3,4-c]pyrrole-2(1H)-carboxylic acid, hexahydro-5-(3-pyridinyl)-, 1,1-dimethylethyl ester, (3aR,6aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 370879-64-4 CAPLUS
CN Pyrrolo[3,4-c]pyrrole-2(1H)-carboxylic acid, hexahydro-5-(6-chloro-3-pyridinyl)-, 1,1-dimethylethyl ester, (3aR,6aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 370879-66-6 CAPLUS
CN Pyrrolo[3,4-c]pyrrole, octahydro-2-(6-chloro-3-pyridinyl)-5-methyl-,

(3aR,6aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 370879-68-8 CAPLUS
CN Pyrrolo[3,4-c]pyrrole-2(1H)-carboxylic acid, hexahydro-5-(3-quinolinyl)-, 1,1-dimethylethyl ester, (3aR,6aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



514-314
546-175

RN 370879-70-2 CAPLUS
CN Pyrrolo[3,4-c]pyrrole-2(1H)-carboxylic acid, hexahydro-5-[5-(phenylmethoxy)-3-pyridinyl]-, 1,1-dimethylethyl ester, (3aR,6aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 370879-71-3 CAPLUS
CN Pyrrolo[3,4-c]pyrrole-2(1H)-carboxylic acid, hexahydro-5-(5-hydroxy-3-pyridinyl)-, 1,1-dimethylethyl ester, (3aR,6aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 370879-73-5 CAPLUS
CN Pyrrolo[3,4-c]pyrrole-2(1H)-carboxylic acid, hexahydro-5-(5-methoxy-3-pyridinyl)-, 1,1-dimethylethyl ester, (3aR,6aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 370879-75-7 CAPLUS
CN Pyrrolo[3,4-c]pyrrole-2(1H)-carboxylic acid, 5-(5-ethoxy-3-pyridinyl)hexahydro-, 1,1-dimethylethyl ester, (3aR,6aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 370879-79-1 CAPLUS
CN Pyrrolo[3,4-c]pyrrole-2(1H)-carboxylic acid, hexahydro-5-(5-propoxy-3-pyridinyl)-, 1,1-dimethylethyl ester, (3aR,6aS)-rel- (9CI) (CA INDEX

NAME)

Relative stereochemistry.



RN 370879-81-5 CAPLUS
CN Pyrrolo[3,4-c]pyrrole-2(1H)-carboxylic acid, hexahydro-5-(6-chloro-5-methoxy-3-pyridinyl)-, 1,1-dimethylethyl ester, (3aR,6aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 370879-83-7 CAPLUS
CN Pyrrolo[3,4-c]pyrrole-2(1H)-carboxylic acid, hexahydro-5-(6-chloro-5-methyl-3-pyridinyl)-, 1,1-dimethylethyl ester, (3aR,6aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 370879-88-2 CAPLUS

CN Pyrrolo[3,4-c]pyrrole-2(1H)-carboxylic acid, hexahydro-5-[5-(2,2,2-trifluoroethoxy)-3-pyridinyl]-, 1,1-dimethylethyl ester, (3aR,6aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 370879-90-6 CAPLUS
CN Pyrrolo[3,4-b]pyrrole, 5-(6-chloro-3-pyridinyl)octahydro-1-(phenylmethyl)-, (3aR,6aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 370880-10-7 CAPLUS
CN Pyrrolo[3,4-b]pyrrole-1(2H)-carboxylic acid, 5-(6-chloro-3-pyridinyl)hexahydro-, 1,1-dimethylethyl ester, (3aR,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 370880-17-4 CAPLUS
CN Pyrrolo[3,4-b]pyrrole-1(2H)-carboxylic acid, 5-(6-chloro-3-pyridinyl)hexahydro-, 1,1-dimethylethyl ester, (3aS,6aS)- (9CI) (CA INDEX

NAME)

Absolute stereochemistry.



RN 370880-33-4 CAPLUS
CN 1H-Pyrrolo[3,4-b]pyridine-1-carboxylic acid, 6-(6-chloro-3-pyridinyl)octahydro-, 1,1-dimethylethyl ester, (4aR,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



514 - 300
546 - 113

RN 370880-35-6 CAPLUS
CN 1H-Pyrrolo[3,4-b]pyridine-1-carboxylic acid, octahydro-6-(3-pyridinyl)-, 1,1-dimethylethyl ester, (4aR,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 370880-37-8 CAPLUS
CN Pyrrolo[3,4-b]pyrrole-1(2H)-carboxylic acid, 5-(5,6-dichloro-3-pyridinyl)hexahydro-, 1,1-dimethylethyl ester, (3aR,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 370880-39-0 CAPLUS
CN Pyrrolo[3,4-b]pyrrole-1(2H)-carboxylic acid, 5-(5,6-dichloro-3-pyridinyl)hexahydro-, 1,1-dimethylethyl ester, (3aS,6aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 370880-41-4 CAPLUS
CN Pyrrolo[3,4-b]pyrrole-1(2H)-carboxylic acid, 5-(6-chloro-5-methyl-3-pyridinyl)hexahydro-, 1,1-dimethylethyl ester, (3aS,6aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 370880-43-6 CAPLUS
CN Pyrrolo[3,4-b]pyrrole-1(2H)-carboxylic acid, 5-(6-chloro-5-methyl-3-pyridinyl)hexahydro-, 1,1-dimethylethyl ester, (3aR,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 370880-45-8 CAPLUS
CN Pyrrolo[3,4-b]pyrrole-1(2H)-carboxylic acid, hexahydro-5-(3-pyridinyl)-, 1,1-dimethylethyl ester, (3aR,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 370880-47-0 CAPLUS
CN Pyrrolo[3,4-b]pyrrole-1(2H)-carboxylic acid, hexahydro-5-(5-methoxy-3-pyridinyl)-, 1,1-dimethylethyl ester, (3aR,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 370880-50-5 CAPLUS
CN Pyrrolo[3,4-b]pyrrole-1(2H)-carboxylic acid, hexahydro-5-(3-pyridinyl)-, 1,1-dimethylethyl ester, (3aS,6aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 370880-53-8 CAPLUS
CN Pyrrolo[3,4-b]pyrrole-1(2H)-carboxylic acid, 5-(5-bromo-3-pyridinyl)hexahydro-, 1,1-dimethylethyl ester, (3aS,6aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 370880-56-1 CAPLUS
CN Pyrrolo[3,4-b]pyrrole-1(2H)-carboxylic acid, hexahydro-5-(5-methoxy-3-pyridinyl)-, 1,1-dimethylethyl ester, (3aS,6aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 370880-65-2 CAPLUS
CN Pyrrolo[3,4-b]pyrrole-1(2H)-carboxylic acid, hexahydro-5-[5-[(trimethylsilyl)ethynyl]-3-pyridinyl]-, 1,1-dimethylethyl ester, (3aR,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 370880-66-3 CAPLUS
CN Pyrrolo[3,4-b]pyrrole-1(2H)-carboxylic acid, 5-(5-ethynyl-3-pyridinyl)hexahydro-, 1,1-dimethylethyl ester, (3aR,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 370880-68-5 CAPLUS
CN Pyrrolo[3,4-b]pyrrole-1(2H)-carboxylic acid, 5-(5-bromo-3-pyridinyl)hexahydro-, 1,1-dimethylethyl ester, (3aR,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 370880-70-9 CAPLUS
CN Pyrrolo[3,4-b]pyrrole-1(2H)-carboxylic acid, 5-(5-cyano-3-pyridinyl)hexahydro-, 1,1-dimethylethyl ester, (3aR,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 370880-80-1 CAPLUS
CN 3,6-Diazabicyclo[3.2.0]heptane-6-carboxylic acid, 3-(3-pyridinyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



514-338
546-276.7

RN 370880-90-3 CAPLUS
CN 3,6-Diazabicyclo[3.2.0]heptane, 3-(6-chloro-3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 370880-92-5 CAPLUS
CN 3,6-Diazabicyclo[3.2.0]heptane-6-carboxylic acid, 3-(6-chloro-3-pyridinyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 370881-03-1 CAPLUS
CN Pyrrolo[3,4-b]pyrrole-1(2H)-carboxylic acid, 5-(6-bromo-5-methoxy-3-pyridinyl)hexahydro-, 1,1-dimethylethyl ester, hydrochloride (4:7),

(3aR,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●7/4 HCl

RN 370881-31-5 CAPLUS
CN Pyrrolo[3,4-b]pyrrole-1(2H)-carboxylic acid, 5-(6-bromo-5-cyano-3-pyridinyl)hexahydro-, 1,1-dimethylethyl ester, (3aR,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 370881-77-9 CAPLUS
CN Pyrrolo[3,4-b]pyrrole-1(2H)-carboxylic acid, 5-(5-ethenyl-3-pyridinyl)hexahydro-, 1,1-dimethylethyl ester, (3aR,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 370881-78-0 CAPLUS
CN Pyrrolo[3,4-b]pyrrole, 5-(5-ethenyl-3-pyridinyl)octahydro-, (3aR,6aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 370881-82-6 CAPLUS
CN Pyrrolo[3,4-b]pyrrole-1(2H)-carboxylic acid, hexahydro-6-(5-methyl-3-pyridinyl)-, 1,1-dimethylethyl ester, (3aR,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 370881-83-7 CAPLUS
CN Pyrrolo[3,4-b]pyrrole, octahydro-5-(5-methyl-3-pyridinyl)-, (3aR,6aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 370881-87-1 CAPLUS
CN Pyrrolo[3,4-b]pyrrole, 5-(6-bromo-5-methyl-3-pyridinyl)octahydro-, (3aR,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 370882-03-4 CAPLUS
CN Pyrrolo[3,4-b]pyrrole-1(2H)-carboxylic acid, 5-(5-ethyl-3-pyridinyl)hexahydro-, 1,1-dimethylethyl ester, (3aR,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 370882-04-5 CAPLUS
CN 3-Pyridinemethanol, 2-bromo-5-[(3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 370882-06-7 CAPLUS
CN Pyrrolo[3,4-b]pyrrole-1(2H)-carboxylic acid, hexahydro-5-[5-(hydroxymethyl)-3-pyridinyl]-, 1,1-dimethylethyl ester, (3aR,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 370882-07-8 CAPLUS
CN Pyrrolo[3,4-b]pyrrole-1(2H)-carboxylic acid, 5-[6-bromo-5-(hydroxymethyl)-3-pyridinyl]hexahydro-, 1,1-dimethylethyl ester, (3aR,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 370882-09-0 CAPLUS
CN Pyrrolo[3,4-b]pyrrole-1(2H)-carboxylic acid, 5-(6-bromo-5-ethenyl-3-pyridinyl)hexahydro-, 1,1-dimethylethyl ester, (3aR,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 370882-10-3 CAPLUS
CN Pyrrolo[3,4-b]pyrrole, 5-(6-bromo-5-ethenyl-3-pyridinyl)octahydro-, (3aR,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 370882-11-4 CAPLUS
CN 3-Pyridineacetonitrile, 2-bromo-5-[(3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 370882-13-6 CAPLUS
CN Pyrrolo[3,4-b]pyrrole-1(2H)-carboxylic acid, 5-[6-bromo-5-[[(methylsulfonyl)oxy]methyl]-3-pyridinyl]hexahydro-, 1,1-dimethylethyl ester, (3aR,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 370882-15-8 CAPLUS
CN Pyrrolo[3,4-b]pyrrole, 5-[6-bromo-5-(methoxymethyl)-3-pyridinyl]octahydro-, (3aR,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 370882-17-0 CAPLUS
CN Pyrrolo[3,4-b]pyrrole-1(2H)-carboxylic acid, 5-[6-bromo-5-(methoxymethyl)-

3-pyridinyl]hexahydro-, 1,1-dimethylethyl ester, (3aR,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 370882-62-5 CAPLUS
CN 3,6-Diazabicyclo[3.2.0]heptane-6-carboxylic acid, 3-(5-cyano-3-pyridinyl)-, 1,1-dimethylethyl ester, (1S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 370882-67-0 CAPLUS
CN 3,6-Diazabicyclo[3.2.0]heptane-6-carboxylic acid, 3-(6-chloro-3-pyridinyl)-, 1,1-dimethylethyl ester, (1S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **370879-51-9P**, cis-2-(3-Pyridinyl)octahydropyrrolo[3,4-c]pyrrole

dihydrochloride **370879-61-1P**, cis-2-Methyl-5-(3-pyridinyl)octahydropyrrolo[3,4-c]pyrrole dihydrochloride **370879-63-3P**, cis-2-(6-Chloro-3-pyridinyl)octahydropyrrolo[3,4-c]pyrrole monohydrochloride **370879-65-5P**, cis-2-(6-Chloro-3-pyridinyl)-5-methyloctahydropyrrolo[3,4-c]pyrrole dihydrochloride **370879-67-7P**, cis-2-(3-Quinolinyl)octahydropyrrolo[3,4-c]pyrrole dihydrochloride **370879-69-9P**, cis-2-(5-Hydroxy-3-pyridinyl)octahydropyrrolo[3,4-c]pyrrole dihydrochloride **370879-72-4P**, cis-2-(5-Methoxy-3-pyridinyl)octahydropyrrolo[3,4-c]pyrrole dihydrochloride **370879-74-6P**, cis-2-(5-Ethoxy-3-pyridinyl)octahydropyrrolo[3,4-c]pyrrole dihydrochloride **370879-76-8P**, cis-2-(5-Propoxy-3-pyridinyl)octahydropyrrolo[3,4-c]pyrrole **370879-77-9P**, cis-2-(5-Propoxy-3-pyridinyl)octahydropyrrolo[3,4-c]pyrrole semi(fumarate) **370879-80-4P**, cis-2-(6-Chloro-5-methoxy-3-pyridinyl)octahydropyrrolo[3,4-c]pyrrole dihydrochloride **370879-82-6P**, cis-2-(6-Chloro-5-methyl-3-pyridinyl)octahydropyrrolo[3,4-c]pyrrole dihydrochloride **370879-85-9P**, cis-2-[5-(2,2,2-Trifluoroethoxy)-3-pyridinyl]octahydropyrrolo[3,4-c]pyrrole dihydrochloride **370879-89-3P**, cis-5-(6-Chloro-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole monohydrochloride **370879-96-2P**, (3AR,6aR)-5-(6-chloro-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole dihydrochloride **370880-11-8P**, (3AS,6aS)-5-(6-chloro-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole dihydrochloride **370880-32-3P**, cis-6-(6-Chloro-3-pyridinyl)octahydro-1H-pyrrolo[3,4-b]pyridine dihydrochloride **370880-34-5P**, cis-6-(3-Pyridinyl)octahydro-1H-pyrrolo[3,4-b]pyridine dihydrochloride **370880-36-7P**, (3AR,6aR)-5-(5,6-dichloro-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole monohydrochloride **370880-38-9P**, (3AS,6aS)-5-(5,6-dichloro-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole monohydrochloride **370880-40-3P**, (3AS,6aS)-5-(6-chloro-5-methyl-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole hydrochloride (5:9) **370880-42-5P**, (3AR,6aR)-5-(6-chloro-5-methyl-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole hydrochloride (4:7) **370880-44-7P**, (3AR,6aR)-5-(3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole dihydrochloride **370880-46-9P**, (3AR,6aR)-5-(5-methoxy-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole dihydrochloride **370880-48-1P**, (3AS,6aS)-5-(3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole **370880-49-2P**, (3AS,6aS)-5-(3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole mono(4-methylbenzenesulfonate) **370880-51-6P**, (3AS,6aS)-5-(5-bromo-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole **370880-52-7P**, (3AS,6aS)-5-(5-bromo-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole mono(4-methylbenzenesulfonate) **370880-54-9P**, (3AS,6aS)-5-(5-methoxy-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole **370880-55-0P**, (3AS,6aS)-5-(5-methoxy-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole mono(4-methylbenzenesulfonate) **370880-64-1P**, (3AR,6aR)-5-(5-ethynyl-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole dihydrochloride **370880-67-4P**, (3AR,6aR)-5-(5-bromo-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole dihydrochloride **370880-69-6P 370880-71-0P**, 5-[(3AR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl]nicotinonitrile monofumarate **370880-72-1P**, cis-3-(3-Pyridinyl)-3,6-diazabicyclo[3.2.0]heptane **370880-73-2P**, cis-3-(3-Pyridinyl)-3,6-diazabicyclo[3.2.0]heptane bis(4-methylbenzenesulfonate) **370880-91-4P**, cis-3-(6-Chloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane hemifumarate

370881-02-0P, (3AR,6aR)-5-(6-bromo-5-methoxy-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole **370881-29-1P**, 5-[(3AR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl]-2-bromonicotinonitrile **370881-30-4P**, 5-[(3AR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl]-2-bromonicotinonitrile monofumarate **370881-75-7P**, (3AR,6aR)-5-(5-vinyl-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole dihydrochloride **370881-84-8P**, (3AR,6aR)-5-(6-bromo-5-chloro-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole **370881-85-9P**, (3AR,6aR)-5-(6-bromo-5-chloro-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole monofumarate **370881-86-0P**, (3AR,6aR)-5-(6-bromo-5-methyl-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole dihydrochloride **370882-02-3P**, (3AR,6aR)-5-(5-ethyl-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole **370882-05-6P**, [5-[(3AR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl]-2-bromo-3-pyridinyl]methanol monofumarate **370882-08-9P**, (3AR,6aR)-5-(6-bromo-5-vinyl-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole dihydrochloride **370882-12-5P**, [5-[(3AR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl]-2-bromo-3-pyridinyl]acetonitrile monofumarate **370882-14-7P**, tert-Butyl (3aR,6aR)-5-[6-bromo-5-(cyanomethyl)-3-pyridinyl]hexahydropyrrolo[3,4-b]pyrrole-1(2H)-carboxylate **370882-16-9P**, (3AR,6aR)-5-[6-bromo-5-(methoxymethyl)-3-pyridinyl]octahydropyrrolo[3,4-b]pyrrole monofumarate **370882-60-3P**, 5-[(1R,5R)-3,6-Diazabicyclo[3.2.0]hept-3-yl]nicotinonitrile **370882-61-4P**, 5-[(1R,5R)-3,6-Diazabicyclo[3.2.0]hept-3-yl]nicotinonitrile monofumarate **370882-63-6P**, (1R,5R)-3-(6-Chloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane **370882-64-7P**, (1R,5R)-3-(6-Chloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane fumarate (10:11) **370883-36-6P**, (3AR,6aR)-5-(6-chloro-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole **370883-37-7P**, (3AS,6aS)-5-(6-chloro-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole **370883-38-8P**, (3AR,6aR)-5-(5,6-dichloro-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole **370883-39-9P**, (3AS,6aS)-5-(5,6-dichloro-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole **370883-40-2P**, (3AS,6aS)-5-(6-chloro-5-methyl-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole **370883-41-3P**, (3AR,6aR)-5-(6-chloro-5-methyl-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole **370883-42-4P**, (3AR,6aR)-5-(3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole **370883-43-5P**, (3AR,6aR)-5-(5-methoxy-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole **370883-44-6P**, (3AR,6aR)-5-(5-ethynyl-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole **370883-45-7P**, (3AR,6aR)-5-(5-bromo-3-pyridinyl)octahydropyrrolo[3,4-b]pyrrole **370883-46-8P**, 5-[(3AR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl]nicotinonitrile **370883-47-9P**, cis-2-(3-Pyridinyl)octahydropyrrolo[3,4-c]pyrrole **370883-48-0P**, cis-2-Methyl-5-(3-pyridinyl)octahydropyrrolo[3,4-c]pyrrole **370883-49-1P**, cis-2-(6-Chloro-3-pyridinyl)octahydropyrrolo[3,4-c]pyrrole **370883-50-4P**, cis-2-(3-Quinolinyl)octahydropyrrolo[3,4-c]pyrrole **370883-52-6P**, cis-2-(5-Hydroxy-3-pyridinyl)octahydropyrrolo[3,4-c]pyrrole **370883-54-8P**, cis-2-(5-Methoxy-3-pyridinyl)octahydropyrrolo[3,4-c]pyrrole **370883-56-0P**, cis-2-(5-Ethoxy-3-pyridinyl)octahydropyrrolo[3,4-c]pyrrole **370883-59-3P**, cis-2-(6-Chloro-5-methoxy-3-pyridinyl)octahydropyrrolo[3,4-c]pyrrole **370883-60-6P**, cis-2-(6-Chloro-5-methyl-3-pyridinyl)octahydropyrrolo[3,4-c]pyrrole **370883-61-7P**, cis-2-[5-(2,2,2-Trifluoroethoxy)-3-pyridinyl]octahydropyrrolo[3,4-c]pyrrole **370883-62-8P**,

cis-6-(6-Chloro-3-pyridinyl)octahydro-1H-pyrrolo[3,4-b]pyridine
370883-63-9P, cis-6-(3-Pyridinyl)octahydro-1H-pyrrolo[3,4-b]pyridine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of diazabicyclic compds. as central nervous system active agents)

RN 370879-51-9 CAPLUS
CN Pyrrolo[3,4-c]pyrrole, octahydro-2-(3-pyridinyl)-, dihydrochloride, (3aR,6aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 370879-61-1 CAPLUS
CN Pyrrolo[3,4-c]pyrrole, octahydro-2-methyl-5-(3-pyridinyl)-, dihydrochloride, (3aR,6aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 370879-63-3 CAPLUS
CN Pyrrolo[3,4-c]pyrrole, 2-(6-chloro-3-pyridinyl)octahydro-, monohydrochloride, (3aR,6aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 370879-65-5 CAPLUS
CN Pyrrolo[3,4-c]pyrrole, octahydro-2-(6-chloro-3-pyridinyl)-5-methyl-, dihydrochloride, (3aR,6aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 370879-67-7 CAPLUS
CN Quinoline, 3-(hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-, dihydrochloride, (3aR,6aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 370879-69-9 CAPLUS
CN 3-Pyridinol, 5-[(3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 370879-72-4 CAPLUS
CN Pyrrolo[3,4-c]pyrrole, octahydro-2-(5-methoxy-3-pyridinyl)-, dihydrochloride, (3aR,6aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 370879-74-6 CAPLUS
CN Pyrrolo[3,4-c]pyrrole, 2-(5-ethoxy-3-pyridinyl)octahydro-, dihydrochloride, (3aR,6aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 370879-76-8 CAPLUS
CN Pyrrolo[3,4-c]pyrrole, octahydro-2-(5-propoxy-3-pyridinyl)-, (3aR,6aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 370879-77-9 CAPLUS
CN Pyrrolo[3,4-c]pyrrole, octahydro-2-(5-propoxy-3-pyridinyl)-, (3aR,6aS)-rel-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 370879-76-8
CMF C14 H21 N3 O

Relative stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 370879-80-4 CAPLUS
CN Pyrrolo[3,4-c]pyrrole, octahydro-2-(6-chloro-5-methoxy-3-pyridinyl)-, dihydrochloride, (3aR,6aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 370879-82-6 CAPLUS
CN Pyrrolo[3,4-c]pyrrole, octahydro-2-(6-chloro-5-methyl-3-pyridinyl)-, dihydrochloride, (3aR,6aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 370879-85-9 CAPLUS
CN Pyrrolo[3,4-c]pyrrole, octahydro-2-[5-(2,2,2-trifluoroethoxy)-3-pyridinyl]-, dihydrochloride, (3aR,6aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 370879-89-3 CAPLUS
CN Pyrrolo[3,4-b]pyrrole, octahydro-5-(6-chloro-3-pyridinyl)-, monohydrochloride, (3aR,6aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 370879-96-2 CAPLUS
CN Pyrrolo[3,4-b]pyrrole, octahydro-5-(6-chloro-3-pyridinyl)-, dihydrochloride, (3aR,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 370880-11-8 CAPLUS
CN Pyrrolo[3,4-b]pyrrole, 5-(6-chloro-3-pyridinyl)octahydro-, dihydrochloride, (3aS,6aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 370880-32-3 CAPLUS
CN 1H-Pyrrolo[3,4-b]pyridine, 6-(6-chloro-3-pyridinyl)octahydro-, dihydrochloride, (4aR,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 370880-34-5 CAPLUS
CN 1H-Pyrrolo[3,4-b]pyridine, octahydro-6-(3-pyridinyl)-, dihydrochloride, (4aR,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 370880-36-7 CAPLUS
CN Pyrrolo[3,4-b]pyrrole, 5-(5,6-dichloro-3-pyridinyl)octahydro-, monohydrochloride, (3aR,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 370880-38-9 CAPLUS
CN Pyrrolo[3,4-b]pyrrole, 5-(5,6-dichloro-3-pyridinyl)octahydro-, monohydrochloride, (3aS,6aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 370880-40-3 CAPLUS
CN Pyrrolo[3,4-b]pyrrole, 5-(6-chloro-5-methyl-3-pyridinyl)octahydro-, hydrochloride (5:9), (3aS,6aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●9/5 HCl

RN 370880-42-5 CAPLUS
CN Pyrrolo[3,4-b]pyrrole, 5-(6-chloro-5-methyl-3-pyridinyl)octahydro-, hydrochloride (4:7), (3aR,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●7/4 HCl

RN 370880-44-7 CAPLUS
CN Pyrrolo[3,4-b]pyrrole, octahydro-5-(3-pyridinyl)-, dihydrochloride, (3aR,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 370880-46-9 CAPLUS
CN Pyrrolo[3,4-b]pyrrole, octahydro-5-(5-methoxy-3-pyridinyl)-, dihydrochloride, (3aR,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 370880-48-1 CAPLUS
CN Pyrrolo[3,4-b]pyrrole, octahydro-5-(3-pyridinyl)-, (3aS,6aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 370880-49-2 CAPLUS
CN Pyrrolo[3,4-b]pyrrole, octahydro-5-(3-pyridinyl)-, (3aS,6aS)-,

mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 370880-48-1
CMF C11 H15 N3

Absolute stereochemistry.



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



RN 370880-51-6 CAPLUS
CN Pyrrolo[3,4-b]pyrrole, 5-(5-bromo-3-pyridinyl)octahydro-, (3aS,6aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 370880-52-7 CAPLUS
CN Pyrrolo[3,4-b]pyrrole, 5-(5-bromo-3-pyridinyl)octahydro-, (3aS,6aS)-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 370880-51-6
CMF C11 H14 Br N3

Absolute stereochemistry.



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



RN 370880-54-9 CAPLUS
CN Pyrrolo[3,4-b]pyrrole, octahydro-5-(5-methoxy-3-pyridinyl)-, (3aS,6aS)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 370880-55-0 CAPLUS
CN Pyrrolo[3,4-b]pyrrole, octahydro-5-(5-methoxy-3-pyridinyl)-, (3aS,6aS)-,
mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 370880-54-9
CMF C12 H17 N3 O

Absolute stereochemistry.



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



RN 370880-64-1 CAPLUS
CN Pyrrolo[3,4-b]pyrrole, 5-(5-ethynyl-3-pyridinyl)octahydro-, dihydrochloride, (3aR,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 370880-67-4 CAPLUS
CN Pyrrolo[3,4-b]pyrrole, 5-(5-bromo-3-pyridinyl)octahydro-, dihydrochloride, (3aR,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 370880-69-6 CAPLUS
CN 3-Pyridinecarbonitrile, 5-[(3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 370880-71-0 CAPLUS
CN 3-Pyridinecarbonitrile, 5-[(3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl]-, rel-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 370880-69-6
CMF C12 H14 N4

Relative stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 370880-72-1 CAPLUS
CN 3,6-Diazabicyclo[3.2.0]heptane, 3-(3-pyridinyl)- (9CI) (CA INDEX NAME)



C1.30

RN 370880-73-2 CAPLUS
CN 3,6-Diazabicyclo[3.2.0]heptane, 3-(3-pyridinyl)-, bis(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 370880-72-1
CMF C10 H13 N3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



RN 370880-91-4 CAPLUS
CN 3,6-Diazabicyclo[3.2.0]heptane, 3-(6-chloro-3-pyridinyl)-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 370880-90-3
CMF C10 H12 Cl N3



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 370881-02-0 CAPLUS
CN Pyrrolo[3,4-b]pyrrole, 5-(6-bromo-5-methoxy-3-pyridinyl)octahydro-, (3aR,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 370881-29-1 CAPLUS
CN 3-Pyridinecarbonitrile, 2-bromo-5-[(3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 370881-30-4 CAPLUS
CN 3-Pyridinecarbonitrile, 2-bromo-5-[(3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 370881-29-1
CMF C12 H13 Br N4

Absolute stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 370881-75-7 CAPLUS
CN Pyrrolo[3,4-b]pyrrole, 5-(5-ethenyl-3-pyridinyl)octahydro-, dihydrochloride, (3aR,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 370881-84-8 CAPLUS
CN Pyrrolo[3,4-b]pyrrole, 5-(6-bromo-5-chloro-3-pyridinyl)octahydro-, (3aR,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 370881-85-9 CAPLUS
CN Pyrrolo[3,4-b]pyrrole, 5-(6-bromo-5-chloro-3-pyridinyl)octahydro-, (3aR,6aR)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 370881-84-8
CMF C11 H13 Br Cl N3

Absolute stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 370881-86-0 CAPLUS
CN Pyrrolo[3,4-b]pyrrole, 5-(6-bromo-5-methyl-3-pyridinyl)octahydro-, dihydrochloride, (3aR,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 370882-02-3 CAPLUS
CN Pyrrolo[3,4-b]pyrrole, 5-(5-ethyl-3-pyridinyl)octahydro-, (3aR,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 370882-05-6 CAPLUS
CN 3-Pyridinemethanol, 2-bromo-5-[(3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl]-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 370882-04-5
CMF C12 H16 Br N3 O

Absolute stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 370882-08-9 CAPLUS
CN Pyrrolo[3,4-b]pyrrole, 5-(6-bromo-5-ethenyl-3-pyridinyl)octahydro-, dihydrochloride, (3aR,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 370882-12-5 CAPLUS
CN 3-Pyridineacetonitrile, 2-bromo-5-[(3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 370882-11-4
CMF C13 H15 Br N4

Absolute stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 370882-14-7 CAPLUS
CN Pyrrolo[3,4-b]pyrrole-1(2H)-carboxylic acid, 5-[6-bromo-5-(cyanomethyl)-3-

pyridinyl]hexahydro-, 1,1-dimethylethyl ester, (3aR,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 370882-16-9 CAPLUS
CN Pyrrolo[3,4-b]pyrrole, 5-[6-bromo-5-(methoxymethyl)-3-pyridinyl]octahydro-, (3aR,6aR)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 370882-15-8
CMF C13 H18 Br N3 O

Absolute stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 370882-60-3 CAPLUS
CN 3-Pyridinecarbonitrile, 5-(1R,5R)-3,6-diazabicyclo[3.2.0]hept-3-yl- (9CI)

(CA INDEX NAME)

Absolute stereochemistry.



C1.30

RN 370882-61-4 CAPLUS
CN 3-Pyridinecarbonitrile, 5-(1R,5R)-3,6-diazabicyclo[3.2.0]hept-3-yl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 370882-60-3
CMF C11 H12 N4

Absolute stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 370882-63-6 CAPLUS
CN 3,6-Diazabicyclo[3.2.0]heptane, 3-(6-chloro-3-pyridinyl)-, (1R,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



cl.30

RN 370882-64-7 CAPLUS
CN 3,6-Diazabicyclo[3.2.0]heptane, 3-(6-chloro-3-pyridinyl)-, (1R,5R)-, (2E)-2-butenedioate (10:11) (9CI) (CA INDEX NAME)

CM 1

CRN 370882-63-6
CMF C10 H12 Cl N3

Absolute stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 370883-36-6 CAPLUS
CN Pyrrolo[3,4-b]pyrrole, 5-(6-chloro-3-pyridinyl)octahydro-, (3aR,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 370883-37-7 CAPLUS
CN Pyrrolo[3,4-b]pyrrole, 5-(6-chloro-3-pyridinyl)octahydro-, (3aS,6aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 370883-38-8 CAPLUS
CN Pyrrolo[3,4-b]pyrrole, 5-(5,6-dichloro-3-pyridinyl)octahydro-, (3aR,6aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 370883-39-9 CAPLUS
CN Pyrrolo[3,4-b]pyrrole, 5-(5,6-dichloro-3-pyridinyl)octahydro-, (3aS,6aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 370883-40-2 CAPLUS
CN Pyrrolo[3,4-b]pyrrole, 5-(6-chloro-5-methyl-3-pyridinyl)octahydro-, (3aS,6aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 370883-41-3 CAPLUS
CN Pyrrolo[3,4-b]pyrrole, 5-(6-chloro-5-methyl-3-pyridinyl)octahydro-, (3aR,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 370883-42-4 CAPLUS
CN Pyrrolo[3,4-b]pyrrole, octahydro-5-(3-pyridinyl)-, (3aR,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 370883-43-5 CAPLUS
CN Pyrrolo[3,4-b]pyrrole, octahydro-5-(5-methoxy-3-pyridinyl)-, (3aR,6aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 370883-44-6 CAPLUS
CN Pyrrolo[3,4-b]pyrrole, 5-(5-ethynyl-3-pyridinyl)octahydro-, (3aR,6aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 370883-45-7 CAPLUS
CN Pyrrolo[3,4-b]pyrrole, 5-(5-bromo-3-pyridinyl)octahydro-, (3aR,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 370883-46-8 CAPLUS
CN 3-Pyridinecarbonitrile, 5-[(3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 370883-47-9 CAPLUS
CN Pyrrolo[3,4-c]pyrrole, octahydro-2-(3-pyridinyl)-, (3aR,6aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 370883-48-0 CAPLUS
CN Pyrrolo[3,4-c]pyrrole, octahydro-2-methyl-5-(3-pyridinyl)-, (3aR,6aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 370883-49-1 CAPLUS
CN Pyrrolo[3,4-c]pyrrole, 2-(6-chloro-3-pyridinyl)octahydro-, (3aR,6aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 370883-50-4 CAPLUS
CN Quinoline, 3-[(3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 370883-52-6 CAPLUS
CN 3-Pyridinol, 5-[(3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 370883-54-8 CAPLUS
CN Pyrrolo[3,4-c]pyrrole, octahydro-2-(5-methoxy-3-pyridinyl)-, (3aR,6aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 370883-56-0 CAPLUS
CN Pyrrolo[3,4-c]pyrrole, octahydro-2-(5-ethoxy-3-pyridinyl)-, (3aR,6aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 370883-59-3 CAPLUS
CN Pyrrolo[3,4-c]pyrrole, 2-(6-chloro-5-methoxy-3-pyridinyl)octahydro-, (3aR,6aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 370883-60-6 CAPLUS
CN Pyrrolo[3,4-c]pyrrole, 2-(6-chloro-5-methyl-3-pyridinyl)octahydro-, (3aR,6aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 370883-61-7 CAPLUS
CN Pyrrolo[3,4-c]pyrrole, octahydro-2-[5-(2,2,2-trifluoroethoxy)-3-pyridinyl]-, (3aR,6aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 370883-62-8 CAPLUS
CN 1H-Pyrrolo[3,4-b]pyridine, 6-(6-chloro-3-pyridinyl)octahydro-, (4aR,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 370883-63-9 CAPLUS
CN 1H-Pyrrolo[3,4-b]pyridine, octahydro-6-(3-pyridinyl)-, (4aR,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L18 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2002 ACS
AN 2001:573269 CAPLUS
DN 135:152805
TI Preparation of benzimidazoles as ORL1-receptor agonists for analgesics
IN Ito, Fumitaka; Noguchi, Hirohide; Ohashi, Yoriko; Shimokawa, Hirohisa
PA Pfizer Pharmaceutical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 39 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2001213878	A2	20010807	JP 2000-396414	20001227
	EP 1122257	A1	20010808	EP 2000-311316	20001218
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US 2002049212	A1	20020425	US 2001-753954	20010103
	BR 2001000014	A	20010828	BR 2001-14	20010104
PRAI	US 2000-174542P	P	20000105		

OS MARPAT 135:152805
GI



I

AB Title compds. I [R1 = C3-11 cycloalkyl, C6-16 bicycloalkyl, C6-16 tricycloalkyl, C8-16 tetracycloalkyl, etc.; A = (un)substituted C1-7 alkyl, C2-5 alkenyl, C2-5 alkynyl, aryl, etc.; M = single bond, CH2,O, S, SO, SO2, CO, NH, etc.; Y = 4- to 12-membered bicyclic carbon ring, 4- to 12- membered bicyclic hetero ring, 5- to 17-membered spiro carbon ring, 5- to 17-membered spiro hetero ring; Z1-Z4 = (un)substituted C1-4 alkyl, C1-4 alkoxy, C1-4 alkylsulfonyl, C1-4 alkylcarbonyl, carboxy, etc.] or their salts are prepd. Tert-Bu 3-[1-[1-(1-phenylcycloheptyl)-4-piperidinyl]-1H-benzimidazol-2-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate was treated with F3CCO2H in CH2Cl2 at room temp. for 0.5 h to give 77.6% 2-(3,8-diazabicyclo[3.2.1]oct-3-yl)-1-[1-(1-phenylcycloheptyl)-4-piperidinyl]-1H-benzimidazole HCl salt.

IT **352542-61-1DP**, mesylate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of benzimidazoles as ORL1-receptor agonists for analgesics)

RN 352542-61-1 CAPLUS
CN Pyrrolo[3,4-c]pyrrole-2(1H)-carboxylic acid, hexahydro-1-(hydroxymethyl)-5-[1-[1-(1-methylcyclooctyl)-4-piperidinyl]-1H-benzimidazol-2-yl]-, 1,1-dimethylethyl ester, (1R,3aS,6aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **352542-09-7P 352542-11-1P 352542-20-2P**
352542-21-3P 352542-22-4P 352542-23-5P
352542-24-6P 352542-25-7P 352542-38-2P
352542-39-3P 352542-40-6P 352542-41-7P
352542-50-8P 352542-51-9P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of benzimidazoles as ORL1-receptor agonists for analgesics)

RN 352542-09-7 CAPLUS

CN 1H-Benzimidazole, 2-(hexahydro-5-methylpyrrolo[3,4-c]pyrrol-2(1H)-yl)-1-[1-(1-phenylcycloheptyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 352542-11-1 CAPLUS

CN 1H-Benzimidazole, 2-(hexahydro-5-methylpyrrolo[3,4-c]pyrrol-2(1H)-yl)-1-[1-(1-phenylcycloheptyl)-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 352542-20-2 CAPLUS
CN 1H-Benzimidazole, 2-(hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-1-[1-(1-methylcyclooctyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 352542-21-3 CAPLUS
CN 1H-Benzimidazole, 2-(hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-1-[1-(1-methylcyclooctyl)-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 352542-22-4 CAPLUS
CN 1H-Benzimidazole, 2-(hexahydro-5-methylpyrrolo[3,4-c]pyrrol-2(1H)-yl)-1-[1-(1-methylcyclooctyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 352542-23-5 CAPLUS
CN 1H-Benzimidazole, 2-(hexahydro-5-methylpyrrolo[3,4-c]pyrrol-2(1H)-yl)-1-[1-(1-methylcyclooctyl)-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 352542-24-6 CAPLUS
CN 1H-Benzimidazole, 2-(hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl)-1-[1-(1-methylcyclooctyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 352542-25-7 CAPLUS
CN 1H-Benzimidazole, 2-(hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl)-1-[1-(1-methylcyclooctyl)-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 352542-38-2 CAPLUS
CN 1H-Benzimidazole, 1-[1-(1-methylcyclooctyl)-4-piperidinyl]-2-(octahydro-2H-pyrrolo[3,4-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 352542-39-3 CAPLUS
CN 1H-Benzimidazole, 1-[1-(1-methylcyclooctyl)-4-piperidinyl]-2-(octahydro-2H-pyrrolo[3,4-c]pyridin-2-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 352542-40-6 CAPLUS
CN 1H-Benzimidazole, 1-[1-(1-methylcyclooctyl)-4-piperidinyl]-2-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)- (9CI) (CA INDEX NAME)



RN 352542-41-7 CAPLUS
CN 1H-Benzimidazole, 1-[1-(1-methylcyclooctyl)-4-piperidinyl]-2-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 352542-50-8 CAPLUS
CN 1H-Benzimidazole, 2-(hexahydro-2-methylpyrrolo[3,4-b]pyrrol-5(1H)-yl)-1-[1-

(1-methylcyclooctyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 352542-51-9 CAPLUS
CN 1H-Benzimidazole, 2-(hexahydro-2-methylpyrrolo[3,4-b]pyrrol-5(1H)-yl)-1-[1-(1-methylcyclooctyl)-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L18 ANSWER 5 OF 28 CAPLUS COPYRIGHT 2002 ACS
AN 2001:545673 CAPLUS
DN 135:122511
TI Preparation of 3-aminoquinazoline-2,4-dione antibacterial agents
IN Bird, Paul; Ellsworth, Edmund Lee; Nguyen, Dai Quoc; Sanchez, Joseph Peter; Showalter, Howard Daniel Hollis; Singh, Rajeshwar; Stier, Michael Andrew; Tran, Tuan Phong; Watson, Brian Morgan; Yip, Judy
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 291 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001053273	A1	20010726	WO 2000-US33656	20001212
	W: AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1255739	A1	20021113	EP 2000-984246	20001212
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRAI	US 2000-178252P	P	20000124		
	US 2000-241267P	P	20001018		
	WO 2000-US33656	W	20001212		

OS MARPAT 135:122511
GI



I



II

AB Title compds. (I) [wherein: R1 and R3 = independently H or (un)substituted (cyclo)alkyl, alkenyl, alkynyl, (hetero)aryl, or heterocyclic; independently R5, R6, and R8 = H or (un)substituted alkyl, alkenyl, alkynyl, or halo, NO2, CN, NH2, (di)alkylamino, etc.; or R1 and R8 taken together with the atoms to which they are attached may form an (un)substituted heterocycle; R7 = H or (un)substituted alkyl, alkenyl, alkynyl, (fused) heterocyclic, or (fused) aryl, or halo, NO2, CN, NH2, (di)alkylamino, carboxy, etc.; J and K = independently C or N; and pharmaceutically acceptable salts thereof] were prepd. as antibacterial agents. For example, N'-{4-[3-(tert-butoxycarbonylaminomethyl)pyrrolidin-1-yl]-2-cyclopropylamino-5-fluorobenzoyl}hydrazinecarboxylic acid tert-Bu

ester (multi-step prepn. given) was chlorinated with N-chlorosuccinimide, cyclized with triphosgene in the presence of K2CO3, and deprotected using HCl gas to afford II.bul.HCl. In antibacterial assays, II.bul.HCl exhibited min. inhibitory concns. of 0.13-2.0 .mu.g/mL against an assortment of Gram neg. and Gram pos. organisms, as well as ciprofloxacin resistant E. coli and S. aureus strains. In addn., II.bul.HCl inhibited supercoiling activity of DNA gyrase with IC50 of 1.0 .mu.M.

IT **224189-78-0**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(comparison compd.; prepn. of 3-aminoquinazoline-2,4-dione antibacterial agents via multi-step syntheses involving cyclization of benzoylhydrazinecarboxylates with phosgene)

RN 224189-78-0 CAPLUS

CN 2,4(1H,3H)-Quinazolinedione, 1-cyclopropyl-6-fluoro-3-hydroxy-7-[(4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **351360-24-2P 351366-14-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of 3-aminoquinazoline-2,4-dione antibacterial agents via multi-step syntheses involving cyclization of benzoylhydrazinecarboxylates with phosgene)

RN 351360-24-2 CAPLUS

CN Carbamic acid, [8-chloro-1-cyclopropyl-6-fluoro-7-(hexahydro-5-methylpyrrolo[3,4-c]pyrrol-2(1H)-yl)-1,4-dihydro-2,4-dioxo-3(2H)-quinazolinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 351366-14-8 CAPLUS

CN 1H-Pyrrolo[3,4-b]pyridine-1-carboxylic acid, 6-(3-amino-1-cyclopropyl-6-

fluoro-1,2,3,4-tetrahydro-8-methyl-2,4-dioxo-7-quinazolinyl)octahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT **351362-69-1P 351363-48-9P 351366-04-6P 351371-78-3P 351372-02-6P 351372-52-6P 351372-83-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 3-aminoquinazoline-2,4-dione antibacterial agents via multi-step syntheses involving cyclization of benzoylhydrazinecarboxylates with phosgene)

RN 351362-69-1 CAPLUS

CN Pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione, 3-amino-1-cyclopropyl-6-fluoro-7-[(3aS,7aS)-octahydro-2H-pyrrolo[3,4-c]pyridin-2-yl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● x HCl

RN 351363-48-9 CAPLUS

CN 2,4(1H,3H)-Quinazolinedione, 3-amino-8-chloro-1-cyclopropyl-6-fluoro-7-(hexahydro-5-methylpyrrolo[3,4-c]pyrrol-2(1H)-yl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 351366-04-6 CAPLUS
CN 2,4(1H,3H)-Quinazolinedione, 3-amino-1-cyclopropyl-6-fluoro-8-methyl-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 351371-78-3 CAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione, 3-amino-1-cyclopropyl-6-fluoro-7-(octahydro-2H-pyrrolo[3,4-c]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 351372-02-6 CAPLUS
CN 2,4(1H,3H)-Quinazolinedione, 3-amino-8-chloro-1-cyclopropyl-6-fluoro-7-(hexahydro-5-methylpyrrolo[3,4-c]pyrrol-2(1H)-yl)- (9CI) (CA INDEX NAME)



RN 351372-52-6 CAPLUS
CN 2,4(1H,3H)-Quinazolinedione, 3-amino-1-cyclopropyl-6-fluoro-8-methyl-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)- (9CI) (CA INDEX NAME)



RN 351372-83-3 CAPLUS
CN 2,4(1H,3H)-Quinazolinedione, 3-amino-1-cyclopropyl-6-fluoro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 6 OF 28 CAPLUS COPYRIGHT 2002 ACS
AN 2001:453062 CAPLUS
DN 135:61360
TI Preparation of heteroaryldiazabicycloalkanes as nicotinic cholinergic receptor ligands.
IN Peters, Dan; Olsen, Gunnar M.; Nielsen, Elsebet Ostergaard; Nielsen, Simon Feldbaek; Ahring, Philip K.; Jorgensen, Tino Dyhring
PA Neurosearch A/S, Den.
SO PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001044243	A2	20010621	WO 2000-DK696	20001214
WO 2001044243	A3	20021031		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI DK 1999-1790 A 19991214
OS MARPAT 135:61360
GI



I

AB Title compds. [I; Z = (CH2)n; n = 0-2; R = H, alkyl, aryl, aralkyl, fluorescent group; R1 = (substituted) mono- or polyheterocyclyl], were prepd. as drugs and diagnostic agents (no data). Thus, 3,7-dibenzyl-3,7-diazabicyclo[3.3.1]nonane (prepn. given) was stirred with HCO2H and Pd/C to give crude monobenzyl deriv., which was heated with 2-chloroquinoline at 100.degree. for 1 h to give 7-benzyl-3-(2-quinolinyl)-3,7-diazabicyclo[3.3.1]nonane. I may be useful for the treatment of central nervous system diseases, disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neurodegeneration inflammation, pain, and drug withdrawal symptoms.

IT **345316-85-0P 345316-88-3P 345316-90-7P**
345316-96-3P 345316-97-4P 345316-99-6P
345317-01-3P 345317-03-5P 345317-05-7P
345317-06-8P 345317-07-9P 345317-08-0P
345317-09-1P 345317-10-4P 345317-11-5P
345317-12-6P 345317-13-7P 345317-14-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of heteroaryldiazabicycloalkanes as nicotinic cholinergic receptor ligands)

RN 345316-85-0 CAPLUS
CN Pyrrolo[3,4-c]pyrrole, octahydro-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 345316-88-3 CAPLUS
CN Pyrrolo[3,4-c]pyrrole, 2-(5-ethoxy-3-pyridinyl)octahydro- (9CI) (CA INDEX NAME)



RN 345316-90-7 CAPLUS
CN Pyrrolo[3,4-c]pyrrole, octahydro-2-(5-phenyl-3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 345316-96-3 CAPLUS
CN Pyrrolo[3,4-c]pyrrole, octahydro-2-[5-(1H-pyrrol-1-yl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 345316-97-4 CAPLUS
CN 1H-Indole, 1-[5-(hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 345316-99-6 CAPLUS
CN Pyrrolo[3,4-c]pyrrole, 2-(5-chloro-3-pyridinyl)octahydro- (9CI) (CA INDEX NAME)



RN 345317-01-3 CAPLUS
CN Pyrrolo[3,4-c]pyrrole, 2-(5-bromo-3-pyridinyl)octahydro- (9CI) (CA INDEX NAME)



RN 345317-03-5 CAPLUS
CN Pyrrolo[3,4-c]pyrrole, 2-(5-fluoro-3-pyridinyl)octahydro- (9CI) (CA INDEX NAME)



RN 345317-05-7 CAPLUS
CN Pyrrolo[3,4-c]pyrrole, octahydro-2-(5-iodo-3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 345317-06-8 CAPLUS
CN Pyrrolo[3,4-c]pyrrole, 2-[6-(ethylthio)-3-pyridinyl]octahydro- (9CI) (CA INDEX NAME)



RN 345317-07-9 CAPLUS
CN Pyrrolo[3,4-c]pyrrole, 2-[5-(ethylthio)-3-pyridinyl]octahydro- (9CI) (CA INDEX NAME)



RN 345317-08-0 CAPLUS
CN Pyrrolo[3,4-c]pyrrole, octahydro-2-[5-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 345317-09-1 CAPLUS
CN Pyrrolo[3,4-c]pyrrole, 2-(6-fluoro-3-pyridinyl)octahydro- (9CI) (CA INDEX NAME)



RN 345317-10-4 CAPLUS

CN Pyrrolo[3,4-c]pyrrole, 2-(6-chloro-3-pyridinyl)octahydro- (9CI) (CA INDEX NAME)



RN 345317-11-5 CAPLUS
CN Pyrrolo[3,4-c]pyrrole, 2-(6-bromo-3-pyridinyl)octahydro- (9CI) (CA INDEX NAME)



RN 345317-12-6 CAPLUS
CN Pyrrolo[3,4-c]pyrrole, octahydro-2-(6-iodo-3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 345317-13-7 CAPLUS
CN Pyrrolo[3,4-c]pyrrole, 2-(5-ethyl-3-pyridinyl)octahydro- (9CI) (CA INDEX NAME)



RN 345317-14-8 CAPLUS
CN Pyrrolo[3,4-c]pyrrole, 2-(5-ethynyl-3-pyridinyl)octahydro- (9CI) (CA INDEX NAME)



L18 ANSWER 7 OF 28 CAPLUS COPYRIGHT 2002 ACS
AN 2001:120739 CAPLUS
DN 134:326572
TI Chiral bicyclic phosphoramidites - a new class of ligands for asymmetric catalysis
AU Huttenloch, Oliver; Spieler, Jan; Waldmann, Herbert
CS Max-Planck-Institut fur molekulare Physiologie Abteilung Chemische Biologie, Dortmund, 44227, Germany
SO Chemistry--A European Journal (2001), 7(3), 671-675
CODEN: CEUJED; ISSN: 0947-6539
PB Wiley-VCH Verlag GmbH
DT Journal
LA English
OS CASREACT 134:326572
AB The development of new ligands for catalytic asym. C-C bond formation is of great interest to org. synthesis. The prepn. of new class of chiral phosphoramidites that embody one or two binaphthol units attached to an achiral azabicyclic [3.3.1] or [3.3.0] framework is described. These ligands were easily accessible from (R)-1,1'-binaphthyl-2,2'-dioxaphosphorchloridite and the corresponding heterobicyclic core. They were employed in enantioselective Cu-catalyzed addns. of different dialkylzinc reagents to cyclic and acyclic enones. The chiral ketones were obtained with an enantiomeric ratio up to 91:9. The choice of the best ligand proved to be strongly dependent on each substrate. In addn., ligand derived from 1,5-dimethyl-3,7-diazabicyclo[3.3.0]octane was the most suitable for Rh-catalyzed hydrogenations of .alpha.,.beta.-unsatd. esters, giving rise to di-Me 2-methylsuccinate and Me N-acetylalaninate with enantiomer ratios up to 95:5.
IT **335616-65-4P**
RL: CAT (Catalyst use); SPN (Synthetic preparation); PREP (Preparation); USES (Uses)
(prepn. of chiral bicyclic phosphoramidites as new class of ligands for asym. catalysis)
RN 335616-65-4 CAPLUS
CN Pyrrolo[3,4-c]pyrrole, 2,5-bis[(11bR)-dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin-4-yl]octahydro-3a,6a-dimethyl-, cis- (9CI) (CA INDEX NAME)



RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 8 OF 28 CAPLUS COPYRIGHT 2002 ACS
AN 2000:666717 CAPLUS
DN 133:252420
TI Preparation of heterocyclylmethylene oxazolones as selective .alpha.1-adrenoreceptor antagonists
IN Coffen, David Llewellyn; Dillon, Michael Patrick; Ford, Anthony P. D. W.; Gogas, Kathleen Ruth; Jacobson, Lupita; Li, Zhe; Williams, Timothy James
PA F. Hoffmann-La Roche A.-G., Switz.
SO PCT Int. Appl., 130 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000055143	A1	20000921	WO 2000-EP2200	20000313
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6355641	B1	20020312	US 2000-521185	20000308
PRAI	US 1999-124721P	P	19990317		
	US 1999-124781P	P	19990317		
	US 1999-165312P	P	19991112		

OS MARPAT 133:252420
GI



I





II





AB The title compds. (I) [wherein X = Formula (A), (B) or (C); m = 1-6; n = 0-5; p and q = independently 1-3 with the proviso that when p > 1, q = 1; Y = (CH2)wR3, (CH2)wCOR4, (CH2)wCONHR5, (CH2)wC(NR6)NHR7, (CH2)wSO2R8, (CH2)wNHR9, (CH2)wNHCOR10, (CH2)wNHCONHR11, or (CH2)wNHSO2R12; w = 0-3; Z = CH or N; R1 = cycloalkyl, cycloalkenyl, heterocyclic, or (hetero)aryl; R2a, R2b, and R2c = independently H, (cyclo)alkyl, alkenyl, or aryl(alkyl); or R2a and R2b form a 5- to 7-membered ring with the carbons to which they are attached; R3 = heterocyclic or heteroaryl; R4, R5, R8, R9, R10, R11, and R12 = independently H, (hydroxy)alkyl, alkoxy, alkylthio, alkenyl, cycloalkyl(alkyl), cycloalkenyl(alkyl), heterocyclic(alkyl), aryl(alkyl), or heteroaryl(alkyl); R6 and R7 = independently H, (hydroxy)alkyl, alkenyl, cycloalkyl(alkyl), cycloalkenyl(alkyl), heterocylic(alkyl), aryl(alkyl) or heteroaryl(alkyl)] where prepd. as selective .alpha.1-adrenoreceptor modulators, particularly antagonists. Thus, alkylation of N-phenylpiperazine-1-carboxamidine (prepn. given) with 4-ethoxymethylene-2-naphthalen-1-yl-4H-oxazol-5-one in DMSO gave II. In assays on the pain response to radiant heat and cold allodynia response in neuropathic rats, II had a significant effect at doses ranging from 30 .mu.g/kg to 1000 .mu.g/kg. I were tested in a [3H]prazosin binding assay and found to be selective .alpha.1B-adrenoceptor antagonists. I are useful in the treatment of disorders of the urinary tract, including obstruction of the urinary tract, sexual dysfunction, pain, hypertension, and cardiac dysfunction. Examples of representative pharmaceutical formulations contg. I are also included.

IT **295340-63-5P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of heterocyclylmethylene oxazolones as selective .alpha.1B-adrenoreceptor antagonists by alkylation of ethoxymethylene

oxazolones with heterocycles)
RN 295340-63-5 CAPLUS
CN 5(4H)-Oxazolone, 4-[[5-(1H-benzimidazol-2-yl)hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]methylene]-2-(4-benzofuranyl)- (9CI) (CA INDEX NAME)



IT **295341-57-0P**, 2-(Hexahydropyrrolo[3,4-c]pyrrol-2-yl)-1H-benzimidazole hydrochloride **295341-58-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of heterocyclylmethylene oxazolones as selective .alpha.1B-adrenoreceptor antagonists by alkylation of ethoxymethylene oxazolones with heterocycles)
RN 295341-57-0 CAPLUS
CN 1H-Benzimidazole, 2-(hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 295341-58-1 CAPLUS
CN 1H-Benzimidazole, 2-[hexahydro-5-(phenylmethyl)pyrrolo[3,4-h]pyrrol-2(1H)-yl]- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 9 OF 28 CAPLUS COPYRIGHT 2002 ACS
AN 1999:572661 CAPLUS
DN 131:351212
TI Synthesis and antimicrobial activity of 4H-4-oxoquinolizine derivatives: consequences of structural modification at the C-8 position
AU Ma, Zhenkun; Chu, Daniel T. W.; Cooper, Curt S.; Li, Qun; Fung, Anthony K. L.; Wang, Sanyi; Shen, Linus L.; Flamm, Robert K.; Nilius, Angela M.; Alder, Jeffery D.; Meulbroek, Jonathan A.; Or, Yat Sun
CS Infectious Disease Research, Abbott Laboratories, Abbott Park, IL, 60064-3537, USA
SO Journal of Medicinal Chemistry (1999), 42(20), 4202-4213
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
GI



I

Q=



Q1=



Q2=



AB The antibacterial 4H-4-oxoquinolizines were introduced recently to overcome bacterial resistance to fluoroquinolones. They exhibit potent antibacterial activity against Gram-pos., Gram-neg., and anaerobic organisms and are highly active against some quinolone-resistant bacteria including quinolone-resistant MRSA. Preliminary studies indicated that oxoquinolizines possess distinct activity and toxicity profiles as compared with their parent quinolones. In order to develop a potent antibacterial agent with the desired spectrum of activity, good tolerability, and balanced pharmacokinetic profile, the authors synthesized and evaluated a series of oxoquinolizines with various substituents at the C-8 position I (NR1R2 = Q, Q1, Q2, etc.). Most compds. tested in this study demonstrated better activity against Gram-pos. bacteria than ciprofloxacin and exhibited good susceptibility against ciprofloxacin- and methicillin-resistant S. aureus. While maintaining potent in vitro activity, several compds. showed improved in vivo efficacy over ABT-719 as indicated by the mouse protection test. The current study revealed that the steric and electronic environment, conformation, and abs. stereochem. of the C-8 group are very important to the antibacterial profiles. Structural modifications of the C-8 group

provide a useful means to improve the antibacterial activities, physicochem. properties, and pharmacokinetic profiles. Manipulation of the C-8 group also allows us to generate analogs with the desired spectrum of activity, such as analogs that are selective against respiratory pathogens.

IT **180975-96-6P 181141-54-8P 181141-55-9P 250274-71-6P 250274-72-7P 250274-75-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn., structure, bactericidal activity, and structure-activity relationship of oxoquinolizines)

RN 180975-96-6 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid, 1-cyclopropyl-7-fluoro-8-[(3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl]-9-methyl-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 181141-54-8 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid, 1-cyclopropyl-7-fluoro-8-[(3aS,6aS)-hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl]-9-methyl-4-oxo-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 181141-55-9 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid, 1-cyclopropyl-7-fluoro-8-[(3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl]-9-methyl-4-oxo-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 250274-71-6 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid, 1-cyclopropyl-7-fluoro-8-[(3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]-9-methyl-4-oxo-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 250274-72-7 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid, 1-cyclopropyl-7-fluoro-9-methyl-8-[(4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 250274-75-0 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid, 1-cyclopropyl-7-fluoro-9-methyl-8-[(3aR,7aS)-octahydro-2H-pyrrolo[3,4-c]pyridin-2-yl]-4-oxo-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 10 OF 28 CAPLUS COPYRIGHT 2002 ACS
AN 1999:311055 CAPLUS
DN 130:338119
TI Preparation of 7-substituted 3-hydroxyquinazoline-2,4-diones and related compounds as antibacterial agents.
IN Domagala, John Michael; Ellsworth, Edmund Lee; Huang, Liren; Renau, Thomas Eric; Singh, Rajeshwar; Stier, Michael Andrew
PA Warner Lambert Co., USA
SO PCT Int. Appl., 137 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9921840	A1	19990506	WO 1998-US19877	19980923
	W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HR, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9895039	A1	19990517	AU 1998-95039	19980923
	EP 1028950	A1	20000823	EP 1998-948473	19980923
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	ZA 9809783	A	19990428	ZA 1998-9783	19981027
	US 6331538	B1	20011218	US 2000-508796	20000315
	US 2002115674	A1	20020822	US 2001-971343	20011004
PRAI	US 1997-63556P	P	19971028		
	US 1998-98588P	P	19980831		
	WO 1998-US19877	W	19980923		
	US 2000-508796	A3	20000315		

OS MARPAT 130:338119
GI



I

AB Title compds. [I; R1 = H, (substituted) alkyl, cycloalkyl, heterocyclyl, Ph; R5, R6, R8 = H, F, Cl, Br, NO2, cyano, CF3, alkyl, cycloalkyl, amino, etc.; R7 = R5, (substituted) carbocyclyl, Ph, (fused) heterocyclyl, etc.; R1R8 = (substituted) 6-7 membered (heterocyclic) ring; X, Y = C, N], were prepd. Thus, 1-cyclopropyl-6-fluoro-3-hydroxy-7-(pyrrolidin-1-yl)-1H-quinazoline-2,4-dione (prepn. given) inhibited Staphylococcus aureus with min. inhibitory concn. = 1.0 .mu.g/mL.
IT **224189-79-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 7-substituted 3-hydroxyquinazoline-2,4-diones and related compds. as antibacterial agents)

RN 224189-79-1 CAPLUS

CN 2,4(1H,3H)-Quinazolinedione, 1-cyclopropyl-6-fluoro-3-hydroxy-7-[(4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-, rel-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 224189-78-0
CMF C18 H21 F N4 O3

Relative stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT **224190-98-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of 7-substituted 3-hydroxyquinazoline-2,4-diones and related compds. as antibacterial agents)

RN 224190-98-1 CAPLUS

CN 2,4(1H,3H)-Quinazolinedione, 1-cyclopropyl-6-fluoro-7-[(4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-3-(phenylmethoxy)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 11 OF 28 CAPLUS COPYRIGHT 2002 ACS
AN 1998:665013 CAPLUS
DN 130:47161
TI In vivo efficacy of ABT-255 against drug-sensitive and -resistant Mycobacterium tuberculosis strains
AU Oleksijew, Andy; Meulbroek, Jon; Ewing, Patty; Jarvis, Ken; Mitten, Mike; Paige, Lenette; Tovcimak, Ann; Nukkula, Mike; Chu, Daniel; Alder, Jeffrey D.
CS Experimental Therapeutics and Pharmacology, Abbott Laboratories, Abbott Park, IL, 60064, USA
SO Antimicrobial Agents and Chemotherapy (1998), 42(10), 2674-2677
CODEN: AMACCQ; ISSN: 0066-4804
PB American Society for Microbiology
DT Journal
LA English
AB Current therapy for pulmonary tuberculosis involves 6 mo of treatment with isoniazid, pyrazinamide, rifampin, and ethambutol or streptomycin for reliable treatment efficacy. The long treatment period increases the probability of noncompliance, leading to the generation of multidrug-resistant isolates of Mycobacterium tuberculosis. A treatment option that significantly shortened the course of therapy, or a new class of antibacterial effective against drug-resistant M. tuberculosis would be of value. ABT-255 is a novel 2-pyridone antibacterial agent which demonstrates in vitro potency and in vivo efficacy against drug-susceptible and drug-resistant M. tuberculosis strains. By the Alamar blue redn. technique, the MIC of ABT-255 against susceptible strains of M. tuberculosis ranged from 0.016 to 0.031 .mu.g/mL. The MIC of ABT-255 against rifampin- or ethambutol-resistant M. tuberculosis isolates was 0.031 .mu.g/mL. In a murine model of pulmonary tuberculosis, 4 wk of oral ABT-255 therapy produced a 2- to 5-log10 redn. in viable drug-susceptible M. tuberculosis counts from lung tissue. Against drug-resistant strains of M. tuberculosis, ABT-255 produced a 2- to 3-log10 redn. in viable bacterial counts from lung tissue. ABT-255 is a promising new antibacterial agent with activity against M. tuberculosis.
IT **181141-52-6**, ABT 255
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(in vivo efficacy of ABT-255 against drug-sensitive and -resistant Mycobacterium tuberculosis strains)
RN 181141-52-6 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid, 1-cyclopropyl-7-fluoro-9-methyl-8-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 12 OF 28 CAPLUS COPYRIGHT 2002 ACS
AN 1998:565044 CAPLUS
DN 129:275852
TI Diastereoselective 1,3-dipolar cycloadditions with enantiopure azomethine ylides
AU Enders, Dieter; Meyer, Ilka; Runsink, Jan; Raabe, Gerhard
CS Inst. Organische Chem., Rheinisch-Westfalische Technische Hochschule, Aachen, D-52074, Germany
SO Tetrahedron (1998), 54(36), 10733-10752
CODEN: TETRAB; ISSN: 0040-4020
PB Elsevier Science Ltd.
DT Journal
LA English
OS CASREACT 129:275852
AB Secondary amine derivs. of (4S,5S)-2,2-dimethyl-4-phenyl-1,3-dioxan-5-amine, were heated with a variety of arom. aldehydes in chlorobenzene under reflux. The in situ generated 1,3-dipoles were trapped with fumaric acid ester, fumaric acid nitrile or N-phenylmaleimide, resp., that were present in excess in the reaction mixt. The cycloadducts were formed in 78-91% and 67-100% yield as mixt. of exo/endo-isomers (endo:exo = 30-65:70-35). These isomers were formed as diastereomerically pure compds. (de.gtoreq.96%).
IT **214079-35-3P 214079-36-4P**
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of)
RN 214079-35-3 CAPLUS
CN Pyrrolo[3,4-c]pyrrole-1-carboxylic acid, 2-[(4S,5S)-2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl]octahydro-3-(4-methoxyphenyl)-4,6-dioxo-5-phenyl-, methyl ester, (1S,3S,3aR,6aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 214079-36-4 CAPLUS
CN Pyrrolo[3,4-c]pyrrole-1-carboxylic acid, 2-[(4S,5S)-2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl]octahydro-3-(4-methoxyphenyl)-4,6-dioxo-5-phenyl-, methyl ester, (1S,3S,3aS,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT **214079-29-5P 214079-30-8P 214079-31-9P**
214079-32-0P 214079-33-1P 214079-34-2P
214079-37-5P 214079-38-6P 214079-39-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 214079-29-5 CAPLUS
CN Pyrrolo[3,4-c]pyrrole-1-carboxylic acid, 2-[(4S,5S)-2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl]-3-(4-fluorophenyl)octahydro-4,6-dioxo-5-phenyl-, methyl ester, (1S,3S,3aR,6aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 214079-30-8 CAPLUS
CN Pyrrolo[3,4-c]pyrrole-1-carboxylic acid, 2-[(4S,5S)-2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl]-3-(4-fluorophenyl)octahydro-4,6-dioxo-5-phenyl-, methyl ester, (1S,3S,3aS,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 214079-31-9 CAPLUS
CN Pyrrolo[3,4-c]pyrrole-1-carboxylic acid, 2-[(4S,5S)-2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl]octahydro-4,6-dioxo-3,5-diphenyl-, methyl ester, (1S,3S,3aR,6aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 214079-32-0 CAPLUS
CN Pyrrolo[3,4-c]pyrrole-1-carboxylic acid, 2-[(4S,5S)-2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl]octahydro-4,6-dioxo-3,5-diphenyl-, methyl ester, (1S,3S,3aS,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 214079-33-1 CAPLUS
CN Pyrrolo[3,4-c]pyrrole-1-carboxylic acid, 3-(4-bromophenyl)-2-[(4S,5S)-2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl]octahydro-4,6-dioxo-5-phenyl-, methyl ester, (1S,3S,3aR,6aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 214079-34-2 CAPLUS
CN Pyrrolo[3,4-c]pyrrole-1-carboxylic acid, 3-(4-bromophenyl)-2-[(4S,5S)-2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl]octahydro-4,6-dioxo-5-phenyl-, methyl ester, (1S,3S,3aS,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 214079-37-5 CAPLUS
CN Pyrrolo[3,4-c]pyrrole-1,3(2H,3aH)-dione, 5-[(4S,5S)-2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl]tetrahydro-2,4,6-triphenyl-, (3aR,4S,6S,6aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 214079-38-6 CAPLUS
CN Pyrrolo[3,4-c]pyrrole-1,3(2H,3aH)-dione, 5-[(4S,5S)-2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl]tetrahydro-2,4-diphenyl-, (3aR,4S,6aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 214079-39-7 CAPLUS
CN Pyrrolo[3,4-c]pyrrole-1,3(2H,3aH)-dione, 5-[(4S,5S)-2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl]tetrahydro-2,4-diphenyl-, (3aS,4S,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 13 OF 28 CAPLUS COPYRIGHT 2002 ACS
AN 1998:15734 CAPLUS
DN 128:102006
TI Process for preparation of chiral 3-aminopyrrolidine and analogous bicyclic compounds as intermediates for antibacterial agents
IN Li, Qun; Wang, Wei-bo; Chu, Daniel T.; Hasvold, Lisa Anne
PA Abbott Laboratories, USA
SO U.S., 18 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5703244	A	19971230	US 1996-754641	19961121
	ZA 9709728	A	19980522	ZA 1997-9728	19971029
	TW 385230	B	20000321	TW 1997-86116224	19971030
	WO 9822437	A1	19980528	WO 1997-US21081	19971118
	W: AU, BG, BR, CA, CN, CZ, HU, IL, JP, KR, MX, NO, NZ, PL, RO, SI, SK, TR				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9873004	A1	19980610	AU 1998-73004	19971118
	US 5837868	A	19981117	US 1997-974206	19971119
PRAI	US 1996-754641	A	19961121		
	WO 1997-US21081	W	19971118		

OS CASREACT 128:102006; MARPAT 128:102006
GI



I



II



III



V

AB Claimed is a process for the prepn. of chiral 3-aminopyrrolidine (I; R = C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, or C3-6 cycloalkyl; R1 = H, C1-6 alkyl or an amino-protecting group) and analogous bicyclic derivs. from dihydroxy olefins HOCH2CH:CHCH2OAr (Ar = aryl) by treatment with titanium isopropoxide, an optically active tartrate ester, and tert-Bu hydroperoxide, followed by subsequent alkylation of the intermediate (II;

Ar = aryl) with an alkyl or alkenyl magnesium halide to give HOCH2CHRCH(OH)CH2OCH2Ar (R = same as above), then formation of pyrrolidine ring (III; R, Ar = same as above) by condensation with an arylmethylamine, subsequent chiral replacement of a ring hydroxyl group with an amino group with further protection thereof, optional addnl. substitution closing of the second ring, and hydrogenolysis to remove a ring-nitrogen protecting group. The present invention describes an efficient process for the enantioselective prepn. of chiral 3-aminopyrrolidine, 2,7-diaza-bicyclo[3.3.0]octane, 2,8-diaza-bicyclo[4.3.0]nonane, and 2,9-diaza-bicyclo[5.3.0]decane derivs. which are useful as intermediates in the prepn. of certain pyrido[1,2-a]pyrimidine and quinolone antibacterial agents. Thus, (E)-4-benzyloxy-2-butene-1-ol was added dropwise to a stirred mixt. of di-Et L-(+)-tartrate and titanium isopropoxide in CH2Cl2 at -23.degree., followed by adding a soln. of tert-Bu hydroperoxide in decane at .apprx.-23.degree. to -30.degree. and the reaction mixt. was stored at -25.degree. overnight and stirred at .apprx.-23.degree. to -30.degree. for 7.5 h to give 83% (2S,3S)-3-(benzyloxymethyl)oxirane-2-methanol (IV). EtMgBr in THF was added to CuCN in Et2O at -50.degree. followed by adding a soln. of IV in Et2O at -50.degree. and the reaction mixt. was stirred at -50.degree. to -25.degree. for 4 h to give (2R,3R)-2-ethyl-4-benzyloxybutane-1,3-diol which was hydrogenolyzed over 10% Pd-C in EtOH at 4 atm H pressure at room temp. for 24 h to give (2R,3R)-2-ethylpyrrolidine-1,3,4-triol. The latter compd. underwent Mitsunobu reaction with phthalimide, Ph3P, DEAD in THF followed by treatment with hydrazine, acylation with di-tert-Bu dicarbonate, and hydrogenolysis over Pd-C under H atm. to give (3S,4R)-3-tert-butoxycarbonylamino-4-ethylpyrrolidine. Four quinolizine compds. were also prepd. and tested for antibacterial activity and for example, racemic V.HCl showed min. inhibitory concn. of 0.02 and 0.001 .mu.g/mL against Staphylococcus aureus ATCC 6538P and Escherichia coli Stainless Steel, resp.

IT **181141-52-6P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(process for prepn. of chiral aminopyrrolidine and analogous bicyclic compds. as intermediates for antibacterial agents)

RN 181141-52-6 CAPLUS

CN 4H-Quinolizine-3-carboxylic acid, 1-cyclopropyl-7-fluoro-9-methyl-8-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

IT **201228-12-8P 201228-20-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(process for prepn. of chiral aminopyrrolidine and analogous bicyclic compds. as intermediates for antibacterial agents)

RN 201228-12-8 CAPLUS

CN 4H-Quinolizine-3-carboxylic acid, 1-cyclopropyl-8-[1-[(1,1-dimethylethoxy)carbonyl]octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-7-fluoro-9-methyl-4-oxo-, (4aS-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 201228-20-8 CAPLUS

CN 4H-Quinolizine-3-carboxylic acid, 1-cyclopropyl-8-[1-[(1,1-dimethylethoxy)carbonyl]octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-7-fluoro-9-methyl-4-oxo-, ethyl ester, (4aS-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


t-BuO
O
F
O
O
OEt
N
H
N
S
N
S
Me
H

L18 ANSWER 14 OF 28 CAPLUS COPYRIGHT 2002 ACS
AN 1997:594555 CAPLUS
DN 127:288165
TI Antitumor compounds
IN Tomita, Kyoji; Chiba, Katsumi; Kashimoto, Shigeki; Nakada, Katsuhisa; Shibamori, Koichiro; Chikugi, Yasutomo; Tajima, Masanori; Oue, Tomio
PA Dainippon Pharmaceutical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 74 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 09221424	A2	19970826	JP 1996-351948	19961210
PRAI JP 1995-347310		19951213		

OS MARPAT 127:288165
GI



I

AB The title compds. (I; X = N or C-Rx, with Rx =H, halogen; R1, R2 = H, halogen; R3 = H, carboxyl; R4 = oxo, OH; R5 = H, amino; R6 = substituted cyclic amino groups) and their physiol. acceptable salts are claimed as antitumor drugs. Thus, I were prepd., and their antitumor activities were tested in animal models.

IT **196821-69-9P 196821-73-5P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antitumor compds.)

RN 196821-69-9 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1,4-dihydro-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-1-(2-thiazolyl)-, monohydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 196821-73-5 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 6-fluoro-1,4-dihydro-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-1-(2-thiazolyl)-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L18 ANSWER 15 OF 28 CAPLUS COPYRIGHT 2002 ACS
AN 1997:116497 CAPLUS
DN 126:117990
TI Preparation of quinolizinone- and pyridopyrimidinonecarboxylates as antibacterials
IN Chu, Daniel T.; Li, Qun; Cooper, Curt S.; Fung, Anthony K. L.; Lee, Cheuk M.; Plattner, Jacob J.; Ma, Zhenkun; Wang, Wei-Bo
PA Abbott Laboratories, USA
SO PCT Int. Appl., 412 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9639407	A1	19961212	WO 1996-US8991	19960605
	W: AU, CA, IL, JP, KP, MX				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2222322	AA	19961212	CA 1996-2222322	19960605
	AU 9661530	A1	19961224	AU 1996-61530	19960605
	EP 871628	A1	19981021	EP 1996-919103	19960605
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	JP 11510478	T2	19990914	JP 1996-501420	19960605
PRAI	US 1995-469159	A	19950606		
	US 1996-638112	A	19960529		
	WO 1996-US8991	W	19960605		

OS MARPAT 126:117990
GI



I



II

AB Title compds. [I; A = N or CR6; R1 = halo, (cyclo)alkyl, alkoxy, (un)substituted Ph, etc.; R2 = halo, (cyclo)alkyl, alkoxy, N-contg. heterocyclyl, etc.; R3 = H, halo, alkoxy; R4 = H, alkyl, cation, etc.; R5,R6 = H, halo, alkyl, alkoxy, etc.] were prepd. Thus, 4-FC6H4CH2C(:NH)NH2 was cyclocondensed with NaOCH:CFCO2Et (prepn. given) and the chlorinated product aminated by 1-methylpiperazine to give 5-fluoro-2-(4-fluorobenzyl)-4-(4-methylpiperazino)pyrimidine which was condensed with EtOCH:C(CO2Et)2 and the product cyclized to give, in 2 addnl. steps, title compd. II. Data for biol. activity of I were given.
IT **169748-73-6P 181141-52-6P 181141-53-7P**
181141-54-8P 181141-55-9P 185692-32-4P

185692-33-5P 185692-55-1P 186196-97-4P
186197-31-9P 186197-32-0P 186197-48-8P
186197-76-2P 186198-52-7P 186198-55-0P
186198-56-1P 186293-38-9P 186293-50-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of quinolizinone- and pyridopyrimidinonecarboxylates as antibacterials)

RN 169748-73-6 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid, 1-cyclopropyl-7-fluoro-8-(hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-9-methyl-4-oxo-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 181141-52-6 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid, 1-cyclopropyl-7-fluoro-9-methyl-8-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 181141-53-7 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid, 1-cyclopropyl-7-fluoro-9-methyl-8-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, monohydrochloride, (4aR-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

RN 181141-54-8 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid, 1-cyclopropyl-7-fluoro-8-[(3aS,6aS)-hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl]-9-methyl-4-oxo-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 181141-55-9 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid, 1-cyclopropyl-7-fluoro-8-[(3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl]-9-methyl-4-oxo-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 185692-32-4 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid, 1-cyclopropyl-7-fluoro-8-(hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl)-9-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 185692-33-5 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid, 1-cyclopropyl-7-fluoro-9-methyl-8-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 185692-55-1 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid, 1-cyclopropyl-7-fluoro-9-methyl-8-(octahydro-1-methyl-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 186196-97-4 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid, 1-cyclopropyl-7-fluoro-9-methyl-8-(octahydro-2H-pyrrolo[3,4-c]pyridin-2-yl)-4-oxo-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 186197-31-9 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid, 1-cyclopropyl-7-fluoro-8-(hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl)-9-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 186197-32-0 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid, 1-cyclopropyl-7-fluoro-9-methyl-8-

(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo- (9CI) (CA INDEX NAME)



RN 186197-48-8 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid, 1-cyclopropyl-7-fluoro-8-(hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-9-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 186197-76-2 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid, 1-cyclopropyl-7-fluoro-9-methyl-8-(octahydro-1-methyl-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo- (9CI) (CA INDEX NAME)



RN 186198-52-7 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid, 1-cyclopropyl-7-fluoro-9-methyl-8-(octahydro-2H-pyrrolo[3,4-c]pyridin-2-yl)-4-oxo- (9CI) (CA INDEX NAME)



RN 186198-55-0 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid, 1-cyclopropyl-7-fluoro-8-(hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl)-9-methyl-4-oxo-, (3aR-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186198-56-1 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid, 1-cyclopropyl-7-fluoro-8-(hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl)-9-methyl-4-oxo-, (3aS-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 186293-38-9 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid, 1-cyclopropyl-7-fluoro-9-methyl-8-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, (4aS-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 186293-50-5 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid, 1-cyclopropyl-7-fluoro-9-methyl-8-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, (4aR-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L18 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2002 ACS
AN 1996:754424 CAPLUS
DN 126:101707
TI Synthesis of quinolizinone-type antibacterial compounds
IN Chu, Daniel T.; Li, Qun; Cooper, Curt S.; Fung, Anthony K. L.; Lee, Cheuk M.; Plattner, Jacob J.
PA Abbott Laboratories, USA
SO U.S., 115 pp., Cont.-in-part of U.S. Ser. No. 137,236, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5580872	A	19961203	US 1994-316319	19940930
	US 5599816	A	19970204	US 1995-482249	19950607
	US 5726182	A	19980310	US 1995-484632	19950607
PRAI	US 1990-517780	B2	19900502		
	US 1992-940870	B2	19921027		
	US 1993-137236	B2	19931014		
	US 1994-316319	A2	19940930		
	US 1995-469159	A3	19950606		

OS MARPAT 126:101707
GI



I

AB Antibacterial quinolizinones and related compds. [I; R1 = (halo)alkyl, alkenyl, alkynyl, alkoxy, C3-8 cycloalkyl, (substituted) Ph, halo, CN, NO2, bicycloalkyl, N-contg. arom. heterocyclyl, etc.; R2 = alkyl, alkenyl, C3-8 cycloalkyl, C4-8 cycloalkenyl, NH2, :NH, alkylamino, (substituted) Ph, N-contg. bicyclic or arom. heterocyclyl, etc.; R3 = H, halo, alkoxy; R4 = H, alkyl, cation, prodrug ester group; R5 = H, halo, OH, alkyl, haloalkyl, alkoxy, (substituted) amino; A = N, CR6; R6 = halo, (substituted) alkyl, alkoxy] are prepd. for use in pharmaceutical compns. for treatment of bacterial infections. Thus, 3-fluoro-9-(4-fluorophenyl)-2-(4-methylpiperazin-1-yl)-6H-6-oxopyrido[1,2-a]pyrimidine-7-carboxylic acid (II) showed a MIC of 0.39 and 0.1 .mu.g/mL in vitro against Staphylococcus aureus A5177 and Pseudomonas aeruginosa BMH10, resp. II was prepd. in 6 steps from 5-fluoro-2-(4-fluorobenzyl)-4-hydroxypyrimidine (prepn. given).

IT **185692-32-4P 185692-33-5P 185692-55-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis of quinolizinone-type antibacterial compds.)

RN 185692-32-4 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid, 1-cyclopropyl-7-fluoro-8-

(hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl)-9-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 185692-33-5 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid, 1-cyclopropyl-7-fluoro-9-methyl-8-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 185692-55-1 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid, 1-cyclopropyl-7-fluoro-9-methyl-8-(octahydro-1-methyl-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L18 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2002 ACS
AN 1996:596103 CAPLUS
DN 125:247794
TI Preparation of novel pyridonecarboxylic acid derivatives or their salts as antibacterial agents
IN Yazaki, Akira; Yoshida, Jiro; Niino, Yoshiko; Ohshita, Yoshihiro; Hayashi, Norihiro; Amano, Hirotaka; Hirao, Yuzo; Kuramoto, Yasuhiro
PA Wakunaga Seiyaku Kabushiki Kaisha, Japan
SO PCT Int. Appl., 222 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9623775	A1	19960808	WO 1996-JP152	19960126
	W: AU, BR, CA, CN, HU, JP, KR, MX, RU, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2211681	AA	19950130	CA 1996-2211681	19960126
	AU 9652600	A1	19960821	AU 1996-52600	19960126
PRAI	JP 1995-12673		19950130		
	WO 1996-JP152		19960126		

OS MARPAT 125:247794
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Pyridonecarboxylic acid derivs. [I; R1 = H, protecting group; R2 = NO2, (un)substituted NH2; R3 = halo; R4, R5 = H, halo, alkyl, alkoxy; R6 = H, halo, OH, alkyl, amino; R7 = H, halo; A = N, CX (wherein X = H, halo, alkyl, alkoxy); Z = halo, (un)substituted satd. cyclic amino], broad-spectrum bactericides with extremely low toxicity, are prepd. A mixt. of chloro compd. II, (3S)-3-aminopyrrolidine, and Et3N in DMF was heated with stirring at 90.degree., the mixt. was cooled, dissolved in EtOH and refluxed to give (S)-pyrrolidinyl compd. III, which showed MIC of 0.025 .mu.g/mL against S. aureus 209P, vs. 0.05 with tosufloxacin.

IT **179741-45-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of novel pyridonecarboxylic acid derivs. or their salts as antibacterial agents)

RN 179741-45-8 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-(5-amino-2,4-difluorophenyl)-6-fluoro-7-(hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-1,4-dihydro-4-oxo-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L18 ANSWER 18 OF 28 CAPLUS COPYRIGHT 2002 ACS
AN 1996:574482 CAPLUS
DN 125:221832
TI Preparation of derivatives of 1,6-naphthyridinecarboxylic acids as antibacterials.
IN Bartel, Stephan; Grohe, Klaus; Hagemann, Hermann; Bremm, Klaus-Dieterr; Endermann, Rainer
PA Bayer A.-G., Germany
SO Eur. Pat. Appl., 54 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 726270	A1	19960814	EP 1996-101170	19960129
	EP 726270	B1	20010523		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	DE 19506535	A1	19960814	DE 1995-19506535	19950224
	ES 2158963	T3	20010916	ES 1996-101170	19960129
	JP 08253480	A2	19961001	JP 1996-40599	19960202
	CA 2168921	AA	19960810	CA 1996-2168921	19960206
	US 5811433	A	19980922	US 1997-878683	19970619
PRAI	DE 1995-19504280	A	19950209		
	DE 1995-19506535	A	19950224		
	US 1996-595603	B1	19960202		

OS MARPAT 125:221832
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. [I; R1 = (substituted) alkyl, cycloalkyl, alkenyl, alkoxy, amino, Ph; R2 = H, (substituted) alkyl, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl; X1 = H, halo, Me, CF3; Z = Q1-Q3; R3 = H, OH, amino, CH2OH, aminomethyl; R4 = H, alkyl, cyclopropyl; R41 = H, Me], were prepd. Thus, 7,8-dichloro-1-cyclopropyl-1,4-dihydro-4-oxo-1,6-naphthyridin-3-carboxylic acid (prepn. given) and (3a.alpha.,4.beta.,7.beta.,7a.alpha.)-4-amino-7-methyl-1,3,3a,4,7,7a-hexahydroisoindole were refluxed 6 h in MeCN/DMF to give 82% title compd. (II). II showed a min. inhibitory concn. of 0.25 .mu.g/mL.
IT **181261-32-5P 181261-65-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of derivs. of 1,6-naphthyridinecarboxylic acids as antibacterials)
RN 181261-32-5 CAPLUS
CN 1,6-Naphthyridine-3-carboxylic acid, 8-chloro-1-cyclopropyl-7-(1,4,4a,5,7,7a-hexahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-1,4-dihydro-4-oxo-, (4aS-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 181261-65-4 CAPLUS
CN 1,6-Naphthyridine-3-carboxylic acid, 8-chloro-1-(2-fluorocyclopropyl)-7-(1,4,4a,5,7,7a-hexahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-1,4-dihydro-5-methyl-4-oxo-, [4aS-[4a.alpha.,6(1S*,2R*),7a.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L18 ANSWER 19 OF 28 CAPLUS COPYRIGHT 2002 ACS
AN 1996:485623 CAPLUS
DN 125:142699
TI Preparation of novel quinoline- and naphthyridinecarboxylate derivatives as antibacterial agents
IN Yazaki, Akira; Yoshida, Jiro; Niino, Yoshiko; Ohshita, Yoshihiro; Hayashi, Norihiro; Amano, Hirotaka; Hirao, Yuzo; Kuramoto, Yasuhiro
PA Wakunaga Seiyaku Kabushiki Kaisha, Japan
SO PCT Int. Appl., 221 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9612704	A1	19960502	WO 1995-JP2156	19951020
	W: JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 787720	A1	19970806	EP 1995-934853	19951020
	R: DE, FR, GB				
	US 5910498	A	19990608	US 1997-817603	19970708
PRAI	JP 1994-255046		19941020		
	JP 1995-12673		19950130		
	WO 1995-JP2156		19951020		

OS MARPAT 125:142699
GI



I



II

AB The title compds. [I; R1 = H, protecting group; R2 = NO2, (substituted) amino; R3 = halo; R4, R5 = H, halo, alkyl, alkoxy; A = N, CX (wherein X = H, halo, alkyl, alkoxy); Z = halo, (substituted) satd. cyclic amino group], effective broad-spectrum antibacterial agents, are prepd. Nitration of 2.00 g difluorophenyl compd. II (R2 = H) with KNO3/H2SO4 at room temp. gave 2.08 g nitro compd. II (R2 = NO2). Some I showed MIC as low as <0.013 .mu.g/mL against S. aureus, vs. 0.05 .mu.g/mL with tosufloxacin.

IT **179741-45-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of novel quinoline- and naphthyridinecarboxylate derivs. as

antibacterial agents)

RN 179741-45-8 CAPLUS

CN 1,8-Naphthyridine-3-carboxylic acid, 1-(5-amino-2,4-difluorophenyl)-6-fluoro-7-(hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-1,4-dihydro-4-oxo-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L18 ANSWER 20 OF 28 CAPLUS COPYRIGHT 2002 ACS
AN 1996:422678 CAPLUS
DN 125:221511
TI Synthesis and Structure-Activity Relationships of 2-Pyridones: A Novel Series of Potent DNA Gyrase Inhibitors as Antibacterial Agents
AU Li, Qun; Chu, Daniel T. W.; Claiborne, Akiyo; Cooper, Curt S.; Lee, Cheuk M.; Raye, Kathleen; Berst, Kristine B.; Donner, Pamela; Wang, Weibo; et al.
CS Abbott Laboratories, Abbott Park, IL, 60064-3500, USA
SO Journal of Medicinal Chemistry (1996), 39(16), 3070-3088
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
GI



I



II

AB Two novel series of 2-pyridones, e.g. I (R = 2,4-F2C6H3), II, were synthesized by transposition of the nitrogen of 4-quinolones to the bridgehead position. This subtle interchange of the nitrogen atom with a carbon atom yielded two novel heterocyclic nuclei, pyrido[1,2-a]pyrimidine and quinolizine, which had not previously been evaluated as antibacterial agents and were found to be potent inhibitors of DNA gyrase. Quinolizines with a Me group at the 9-position such as II (ABT-719) demonstrate exceptional broad spectrum antibacterial activity. Most notably, they are active against resistant bacteria such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant strains of enterococci, and ciprofloxacin-resistant organisms. In addn., 2-pyridones also possess favorable physiochem. and pharmacokinetic properties. These 2-pyridones were synthesized from the com. available starting materials by 10-17 linear transformations. The structure of an adduct yielded by this sequence, ABT-719, was detd. by X-ray crystallog. anal.

IT **180975-95-5P 180975-96-6P 181141-52-6P**
181141-53-7P 181141-54-8P 181141-55-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and bactericidal activity of 2-pyridones)

RN 180975-95-5 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid, 1-cyclopropyl-7-fluoro-9-methyl-8-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, dihydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 180975-96-6 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid, 1-cyclopropyl-7-fluoro-8-[(3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl]-9-methyl-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 181141-52-6 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid, 1-cyclopropyl-7-fluoro-9-methyl-8-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 181141-53-7 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid, 1-cyclopropyl-7-fluoro-9-methyl-8-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, monohydrochloride, (4aR-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

RN 181141-54-8 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid, 1-cyclopropyl-7-fluoro-8-[(3aS,6aS)-hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl]-9-methyl-4-oxo-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 181141-55-9 CAPLUS
CN 4H-Quinolizine-3-carboxylic acid, 1-cyclopropyl-7-fluoro-8-[(3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl]-9-methyl-4-oxo-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L18 ANSWER 21 OF 28 CAPLUS COPYRIGHT 2002 ACS
AN 1995:892832 CAPLUS
DN 123:313930
TI Preparation of quinolizinonecarboxylates and analogs as antibacterials
IN Chu, Daniel T.; Li, Qun; Cooper, Curt S.; Fung, Anthony K. L.; Lee, Cheuk M.; Plattner, Jacob J.
PA Abbott Laboratories, USA
SO PCT Int. Appl., 255 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9510519	A1	19950420	WO 1994-US11166	19940930
	W: AU, BR, CA, CN, JP, KR				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9479258	A1	19950504	AU 1994-79258	19940930
	AU 689809	B2	19980409		
	EP 723545	A1	19960731	EP 1994-929998	19940930
	EP 723545	B1	20020508		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	CN 1137273	A	19961204	CN 1994-194479	19940930
	CN 1053188	B	20000607		
	JP 09503783	T2	19970415	JP 1994-511876	19940930
	BR 9407806	A	19970819	BR 1994-7806	19940930
	AT 217309	E	20020515	AT 1994-929998	19940930
PRAI	US 1993-137236	A	19931014		
	WO 1994-US11166	W	19940930		

OS MARPAT 123:313930
GI



I



II

AB Title compds. [I; R1 = halo, (cyclo) alkyl, Ph, heterocyclyl, etc.; R2 = halo, (cyclo)alk(en)yl, Ph, heterocyclyl, etc.; R3 = H, halo, alkoxy; R4 = H, alkyl, cation, ester residue; R5 = H, halo, OH, alkyl, etc.; R6 = alkyl] were prepd. Thus, 3-chlorotetrafluoropyridine was converted in a multistep synthesis to 2-(4-chloro-5-fluoro-3-methyl-2-pyridyl)cyclopropaneacetaldehyde which was condensed with CH2(CO2Et)2 and the product cyclized to give, after amination, title compd. (R)-II.HCl [R = (S)-CH(NH2)Et] which had MIC of 0.05 and 12.5.mu.g/mL against Staphylococcus aureus 1775 and Candida albicans CCH 442, resp.
IT **169748-73-6P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of quinolizinonecarboxylates and analogs as antibacterials)

RN 169748-73-6 CAPLUS

CN 4H-Quinolizine-3-carboxylic acid, 1-cyclopropyl-7-fluoro-8-(hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-9-methyl-4-oxo-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L28 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2002 ACS
AN 1995:408383 CAPLUS
DN 122:290876
TI Preparation of penemylmethyl and cephalosporinylmethyl 7-(diazabicyclonono)quinolonecarboxylates as bactericides
IN Petersen, Uwe; Schroeck, Wilfried; Haebich, Dieter; Krebs, Andreas; Schenke, Thomas; Phillipps, Thomas; Grohe, Klaus; Endermann, Rainer; Bremm, Klaus Dieter; Metzger, Karl Georg
PA Bayer A.-G., Germany
SO Ger. Offen., 46 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 4234330	A1	19940414	DE 1992-4234330	19921012
EP 592868	A1	19940420	EP 1993-115705	19930929
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CA 2108060	AA	19940413	CA 1993-2108060	19931008
JP 06228154	A2	19940816	JP 1993-277331	19931012
PRAI DE 1992-4234330		19921012		

OS MARPAT 122:290876
GI



I







AB Title compds. [I; A = N, CR3; B = O or S; L = (carba)penemylmethyl group Q1, cephalosporinylmethyl group Q2; R = diazabicyclonono group Q; R1 = (cyclo)alkyl, alkenyl, (fluoro)phenyl, OMe, NH2, etc.; R2 = H, Me, Et, alkoxycarbonyl, etc.; R3 = H, halo, Me, alkenyl, alkynyl, OH, OMe; R1R3 = Z1CH2CHMe, OCH2NR4; R4 = H, Me, CHO; R5 = H, CH2Ph, alkyl, etc.; R6 = H, OMe; R7 = H, acyl, alkoxycarbonyl, etc.; X1 = halo; X2 = H, halo, Me, (di)(alkyl)amino, OH, alkoxy, etc.; Y = CH2, CHMe, S; Z = CH2 or O; Z1 = O, S, CH2] were prepd. as bactericides (no data). Thus, Cs 1-cyclopropyl-7-[(1S,6S)-2-tert-butoxycarbonyl-2,8-diazabicyclo[4.3.0]non-8-yl]-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylate was condensed with benzhydryl (6R,7R)-7-phenylacetylamino-3-chloromethyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate to give, after deprotection, (6R,7R)-2-carboxy-8-oxo-7-phenylacetylamino-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-ylmethyl 1-cyclopropyl-7-[(1S,6S)-2,8-diazabicyclo[4.3.0]non-8-yl]-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylate.

IT **151095-98-6P 151096-11-6P 161594-38-3P**
161594-46-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of penemylmethyl and cephalosporinylmethyl 7-(diazabicyclonono)quinolonecarboxylates as bactericides)

RN 151095-98-6 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, (4aS-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 151096-11-6 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, ethyl ester, (4aS-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 161594-38-3 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, hydrochloride, (4aS-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



●x HCl

RN 161594-46-3 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, hydrochloride, (4aS-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



●x HCl

L18 ANSWER 23 OF 28 CAPLUS COPYRIGHT 2002 ACS
AN 1994:630582 CAPLUS
DN 121:230582
TI Quinolonecarboxylic acid .beta.-lactam antibiotics
IN Petersen, Uwe; Schroeck, Wilfried; Haebich, Dieter; Krebs, Andreas; Schenke, Thomas; Philipps, Thomas; Grohe, Klaus; Endermann, Rainer; Bremm, Klaus Dieter; Metzger, Karl Georg
PA Bayer A.-G., Germany
SO Eur. Pat. Appl., 82 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 591808	A1	19940413	EP 1993-115565	19930927
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
DE 4234078	A1	19940414	DE 1992-4234078	19921009
NO 9303393	A	19940411	NO 1993-3393	19930923
AU 9348644	A1	19940421	AU 1993-48644	19930927
AU 666772	B2	19960222		
US 5480879	A	19960102	US 1993-131253	19931001
CA 2107812	AA	19940410	CA 1993-2107812	19931006
FI 9304411	A	19940410	FI 1993-4411	19931007
ZA 9307474	A	19940426	ZA 1993-7474	19931008
HU 66376	A2	19941128	HU 1993-2843	19931008
JP 08020587	A2	19960123	JP 1993-277526	19931008
CN 1090285	A	19940803	CN 1993-118514	19931009

PRAI DE 1992-4234078 19921009
OS MARPAT 121:230582
GI



I



II

AB The title compd. [I; A = N, (un)substituted CH; R1 = C1-4 alkyl, C2-4 alkenyl, C3-6 cycloalkyl, dicyclo[1.1.1]pent-1-yl, etc.; R2 = H, (un)substituted C1-5 alkyl, or (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl; X1 = halogen; X2 = H, amino, alkylamino, dialkylamino, etc.; Z = 26-lactam

residue-contg. (un)substituted substituent], useful as antibiotics for the treatment of bacterial infections, are prepd. Thus, .beta.-lactam II was prepd. and demonstrated min. inhibitory concn. against Staphylococcus aureus (ICB 25701) of 0.25 .mu.g/mL.

IT **151095-98-6P 151096-11-6P 151096-12-7P 158182-91-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction of, in prepn. of antibiotics)

RN 151095-98-6 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, (4aS-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 151096-11-6 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, ethyl ester, (4aS-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 151096-12-7 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, monohydrochloride, (4aS-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 158182-91-3 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-1,4-dihydro-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, monohydrochloride, (4aS-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L28 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2002 ACS
AN 1994:605332 CAPLUS
DN 121:205332
TI Preparation of quinoline-derivative antibiotics
IN Kim, Wan Joo; Park, Tae Ho; Kim, Bong Jin; Kim, Moon Hwan; Pearson, Neil
PA Korea Research Institute of Chemical Technology, S. Korea; SmithKline Beecham PLC
SO PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9415938	A1	19940721	WO 1994-KR5	19940118
	W: AU, CA, CN, JP, NZ, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9458665	A1	19940815	AU 1994-58665	19940118
	EP 690862	A1	19960110	EP 1994-904771	19940118
	EP 690862	B1	20020710		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 08505385	T2	19960611	JP 1994-515886	19940118
	AT 220401	E	20020715	AT 1994-904771	19940118
	US 5770597	A	19980623	US 1995-492086	19951011
PRAI	KR 1993-543	A	19930118		
	WO 1994-KR5	W	19940118		

OS MARPAT 121:205332
GI



I

AB The title compds. [I; A = N, (Y)C:; Y = H, halogen, alkyl, alkoxy, etc.; R1 = (un)substituted C1-3 alkyl or cycloalkyl; R2 = H, lower alkyl; X1 = H, NH2, alkyl, halogen; X2 = H. halogen; Y1, Y2 = H, lower alkyl], useful as broad-spectrum antibiotics, are prepd. Thus, 1-cyclopropyl-6-fluoro-7-[(trans-piperidinopyrrolidine)-8-yl]-8-chloro-1,4-dihydroquinoline-4-oxo-3-carboxylic acid was prepd. and demonstrated MIC against Streptococcus pyogenes (308A) of 0.391 .mu.g/mL, vs. 3.125 .mu.g/mL for ciprofloxacin.

IT **157992-59-1 157992-62-6 158060-79-8**
158060-80-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(antibiotic)

RN 157992-59-1 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-7-(octahydro-2-methyl-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo- (9CI) (CA INDEX NAME)



RN 157992-62-6 CAPLUS
CN 1,8-Naphthyridin-4(1H)-one, 1-(2,4-difluorophenyl)-6-fluoro-3-(nitroacetyl)-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-, monohydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 158060-79-8 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 158060-80-1 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L18 ANSWER 25 OF 28 CAPLUS COPYRIGHT 2002 ACS
AN 1994:164147 CAPLUS
DN 120:164147
TI Preparation of novel quinolone derivative or salt thereof and antibacterial agent containing the same
IN Kuramoto, Yasuhiro; Noda, Shuichiro; Maruyama, Shinobu; Hatono, Shunso; Mochizuki, Haruyo; Yazaki, Akira
PA Wakunaga Seiyaku K. K., Japan; Fujisawa Pharmaceutical Co., Ltd.
SO PCT Int. Appl., 161 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9313091	A1	19930708	WO 1992-JP1712	19921225
	W: CA, JP, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 596126	A1	19940511	EP 1993-900445	19921225
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	US 5412098	A	19950502	US 1993-104137	19930819
PRAI	JP 1991-346577		19911227		
	WO 1992-JP1712		19921225		

OS MARPAT 120:164147
GI



I

AB Heterocyclylquinolone derivs. [I; R1 = H, CO2H-protecting group; R2 = H, halo, lower alkyl; X = H, halo; Y = halo, (un)substituted cyclic amino or cycloalkenyl, R3(CH2)mA; R3 = H, (un)substituted NH2; A = O, S; m = 0-3; Z = N, CR4; R4 = H, halo; W = (un)substituted 5-membered heterocyclyl having 3.gtoreq. hetero atoms including at least 2 N atoms], having potent antibacterial activity with low toxicity and high oral absorbability through oral administration and useful as human and animal drugs, medicines for fish, agrochems., and food preservatives, are prepd. Thus, 7-chloro-6-fluoro-1-(1,2,5-thiadiazol-3-yl)-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid 1.5, 3-(S)-aminopyrrolidine 0.46, and Et3N 1.06 g were stirred at 80.degree. in MeCN for 1 h to give, after workup and crystn. from EtOH, 1.5 g 7-[3-(S)-aminopyrrolidin-1-yl]-6-fluoro-1-(1,2,5-thiadiazol-3-yl)-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid (II). II showed min. inhibitory concn. of <0.013, 0.2, and 0.1 .mu.g/mL against Escherichia coli NIH JC-2, Staphylococcus aureus 209P, and Pseudomonas aeruginosa, resp. A total of 229 I were prepd.

IT **152513-85-4P 152613-25-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as antibacterial agent)

RN 152513-85-4 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 6-fluoro-1,4-dihydro-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-1-(1,2,5-thiadiazol-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 152613-25-7 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 6-fluoro-1,4-dihydro-4-oxo-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-1-(1,2,5-thiadiazol-3-yl)-, monohydrochloride, (4aS-cis)- (9CI) (CA INDEX NAME)



● HCl

L18 ANSWER 26 OF 28 CAPLUS COPYRIGHT 2002 ACS
AN 1994:8616 CAPLUS
DN 120:8616
TI Preparation of (diazabicyclononyl)quinolones and related compounds as antibacterials
IN Petersen, Uwe; Krebs, Andreas; Schenke, Thomas; Philipps, Thomas; Grohe, Klaus; Bremm, Klaus dieter; Endermann, Rainer; Metzger, Karl Georg; Haller, Ingo
PA Bayer A.-G., Germany
SO Eur. Pat. Appl., 68 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 550903	A1	19930714	EP 1992-122058	19921228
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	DE 4200414	A1	19930715	DE 1992-4200414	19920110
	DE 4208789	A1	19930923	DE 1992-4208789	19920319
	DE 4208792	A1	19930923	DE 1992-4208792	19920319
	NO 9204978	A	19930712	NO 1992-4978	19921222
	CZ 289076	B6	20011017	CZ 1992-3966	19921229
	JP 05271229	A2	19931019	JP 1993-15917	19930105
	AU 9331054	A1	19930715	AU 1993-31054	19930106
	AU 669502	B2	19960613		
	CA 2086914	AA	19930711	CA 1993-2086914	19930107
	IL 104331	A1	19970110	IL 1993-104331	19930107
	ZA 9300125	A	19930810	ZA 1993-125	19930108
	HU 64065	A2	19931129	HU 1993-34	19930108
	HU 219488	B	20010428		
	PL 174853	B1	19980930	PL 1993-297338	19930108
	PL 175558	B1	19990129	PL 1993-320107	19930108
	CN 1074218	A	19930714	CN 1993-100215	19930109
	CN 1043142	B	19990428		
	RU 2105770	C1	19980227	RU 1993-4405	19930111
	FI 9701012	A	19970311	FI 1997-1012	19970311
	CN 1192440	A	19980909	CN 1997-108773	19971220
	CN 1061351	B	20010131		
	CN 1212256	A	19990331	CN 1998-109504	19980529
	CN 1075499	B	20011128		
	FI 9900207	A	19990203	FI 1999-207	19990203
	FI 2002000059	A	20020111	FI 2002-59	20020111
PRAI	DE 1992-4200414	A	19920110		
	DE 1992-4208789	A	19920319		
	DE 1992-4208792	A	19920319		
	FI 1993-49	A	19930107		
	IL 1993-90940	A3	19930107		

OS MARPAT 120:8616
GI



I



II







AB Title compds. [I; A = CH, CF, CCl, COMe, CMe, N; X1 = H, halo, NH2, Me; R1 = alkyl, FCH2CH2, cyclopropyl, (halo)phenyl; AR1 = COCH2CHMe; R2 = H, (substituted) alkyl, 5-methyl-2-oxo-1,3-dioxol-4-ylmethyl; B = Q1-Q3, etc.; Y = O, CH2; R3 = oxoalkyl, CH2COPh, R5O2CCH:CCO2R5, CH2CH2CO2R5, CH:CHCO2R5, CH2CH2CN; R4 = H, alkyl, 5-methyl-2-oxo-1,3-dioxol-4-ylmethyl, oxoalkyl, CH2COPh, CH2CH2CO2R5, R5O2CCH:CCO2R5, CH:CHCO2R5, CH2CH2CN; R5 = H, alkyl], were prepd. Thus, 1-cyclopropyl-6,7,8-trifluoro-1,4-dihydro-4-oxo-3-quindolinecarboxylic acid, 1,4-diazabicyclo[2.2.2]octane, and (+)-[S,S]-2,8-diazabicyclo[4.3.0]nonane (prepn. given) were refluxed in DMF to give 84% title compd. II. I were effective against Staph. aureus in mice at 2.5-10 mg/kg orally, vs. 80 mg/kg orally for ciprofloxacin.

IT **151095-98-6P 151096-11-6P 151096-12-7P 151096-27-4P 151213-20-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as antibacterial)

RN 151095-98-6 CAPLUS

CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, (4aS-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 151096-11-6 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, ethyl ester, (4aS-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 151096-12-7 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, monohydrochloride, (4aS-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 151096-27-4 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-7-[1-(3-ethoxy-3-oxo-1-propenyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-6-fluoro-1,4-dihydro-4-oxo-, [4aS-[1(E),4a.alpha.,7a.alpha.]]- (9CI) (CA INDEX NAME)



RN 151213-20-6 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, monohydrochloride, (4aS-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L18 ANSWER 27 OF 28 CAPLUS COPYRIGHT 2002 ACS
AN 1991:408619 CAPLUS
DN 115:8619
TI Synthesis of a new bridged diamine, 3,6-diazabicyclo[3.2.0]heptane: applications to the synthesis of quinolone antibacterials
AU Jacquet, Jean Pierre; Bouzard, Daniel; Kiechel, Jean Rene; Remuzon, Philippe
CS Pharm. Res. Inst., Bristol-Myers Squibb, Marne-la-Vallee, 77422, Fr.
SO Tetrahedron Letters (1991), 32(12), 1565-8
CODEN: TELEAY; ISSN: 0040-4039
DT Journal
LA English
OS CASREACT 115:8619
GI



I



II



III



IV

AB Diprotected 3,6-diazabicyclo[3.2.0]heptane I has been prepd. by a highly efficient process, starting from pyrrolidine II. Debenzylation of I by catalytic hydrogenation, followed by condensation with 7-haloquinolone III (X = CH, R = H, R1 = F) or chloronaphthyridinone III (X = N, R = Et, R1 = Cl) led to the the quinolone IV (X = CH) and naphthyridinone IV (X = N) resp., which are potential antibacterials.

IT **134253-09-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and N-deprotection and ester hydrolysis of)

RN 134253-09-1 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1-(1,1-dimethylethyl)-6-fluoro-1,4-dihydro-4-oxo-7-[6-(trifluoroacetyl)-3,6-diazabicyclo[3.2.0]hept-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)



IT **134253-10-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 134253-10-4 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 7-(3,6-diazabicyclo[3.2.0]hept-3-yl)-1-(1,1-dimethylethyl)-6-fluoro-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



L18 ANSWER 28 OF 28 CAPLUS COPYRIGHT 2002 ACS
AN 1983:488081 CAPLUS
DN 99:88081
TI Synthesis and carbon-13 NMR study of 2-benzyl, 2-methyl, 2-aryloctahydropyrrolo[3,4-c]pyrroles and the 1,2,3,5-tetrahydropyrrolo[3,4-c]pyrrole ring system
AU Ohnmacht, Cyrus J., Jr.; Draper, Clyde W.; Dedinas, Robert F.; Loftus, Philip; Wong, J. J.
CS Stuart Pharm. Div., ICI Americas Inc., Wilmington, DE, 19897, USA
SO Journal of Heterocyclic Chemistry (1983), 20(2), 321-9
CODEN: JHTCAD; ISSN: 0022-152X
DT Journal
LA English
OS CASREACT 99:88081
GI



I II

AB Octahydropyrrolo[3,4-c]pyrroles I (R = CH2Ph, Ph, 3-MeOC6H4, 3-F3CC6H4) were prepd. in 5 steps from 1-benzylpyrrole-3,4-dicarboxylic acid. I (R = Me) was prepd. analogously in 6 steps from 1-methylpyrrole-3,4-dicarboxylic acid. Diborane redn. of 1-benzyl-N-methyl-1H-pyrrole-3,4-dicarboximide and 1,N-dibenzyl-1H-pyrrole-3,4-dicarboximide gave II (R = Me, CH2Ph), the first reported members of the 1,2,3,5-tetrahydropyrrolo[3,4-c]pyrrole ring system. A detailed study of the 13C-NMR shifts permitted a complete assignment for all compds. Mono- and disubstituted products produce a systematic effect on the shifts for the bicyclic ring systems which can be readily interpreted in terms of substituent chem. shifts. The effect of protonation at N produces a series of well defined chem. shifts for the octahydropyrrolo[3,4-c]pyrrole ring system.

IT **86732-38-9P 86732-40-3P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and carbon-13 NMR of)

RN 86732-38-9 CAPLUS
CN Pyrrolo[3,4-c]pyrrole, octahydro-2-(phenylmethyl)-5-(2-thiazolyl)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 86732-37-8
CMF C16 H19 N3 S



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 86732-40-3 CAPLUS
CN Pyrrolo[3,4-c]pyrrole, octahydro-2-(phenylmethyl)-5-(2-pyrimidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT **86732-37-8P 86732-39-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 86732-37-8 CAPLUS
CN Pyrrolo[3,4-c]pyrrole, octahydro-2-(phenylmethyl)-5-(2-thiazolyl)- (9CI) (CA INDEX NAME)



RN 86732-39-0 CAPLUS
CN Pyrrolo[3,4-c]pyrrole, octahydro-2-(phenylmethyl)-5-(2-pyrimidinyl)- (9CI) (CA INDEX NAME)